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MORTALITY AMONG ICU CANCER PATIENTS 
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The University of Texas at Tyler 
July 2017 
 
Cancer patients admitted to the intensive care unit (ICU) may be experiencing 
complications of disease or treatment-related effects. While acute complications related 
to disease and/or its therapeutic management vary in severity, the approach to ICU-
centered care is complicated by actual versus perceived risks of poor outcomes. 
Prognostic models that inform clinical judgment of nurses and physicians may prove 
helpful in this population. The Acute Physiology and Chronic Health Evaluation II 
(APACHE II), Simplified Acute Physiology Score II (SAPS II) and Sequential Organ 
Failure Assessment (SOFA) are ICU-based models predicting 30-day mortality among 
the general ICU population. Although studies have been published on use of each model, 
prognostic accuracy for predicting 30-day, all-cause ICU mortality in the cancer 
population has yielded mixed results.  
The purpose of this study was to determine which prognostic model demonstrated 
greatest prognostic accuracy among oncology patients. Framed within a derived 
Prognostic Framework, a meta-analysis of prospective and retrospective cohort studies 
using literature searches of CINAHL, Cochrane, PubMed and Web of Science databases 
vii 
 
spanning 2000 to 2017 timeframe was performed. Meta-regression with a random-effects 
model was used to summarize area under the receiver-operating characteristic curves 
(AUCs) to estimate overall predictive accuracy for the APACHE II, SAPS II, and SOFA. 
After comparing performances, APACHE II demonstrated greatest predictive accuracy.  
Keywords: Prognostic models, intensive care unit, cancer, meta-analysis, meta-
regression 
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Chapter 1  
Introduction 
  Critically ill oncology patients admitted to the ICU are a vulnerable at- risk population 
for clinical bias towards perceived poor prognoses (Bird et al., 2012; Kopterides et al., 2011; 
Neville et al., 2015). Negative preconceived notions about the clinical response of oncology 
patients to aggressive medical management in the critical care environment are reflective of 
biases and misunderstandings related to cancer diagnoses, traditional treatment methods, and 
past approaches to symptom management (Cruz, Camalionte, & Caruso, 2015; Louie et al., 
2013; Mohammed & Peter, 2009). Perception of prognosis is often demarcated between 
specialists (oncology experts versus critical care professionals) sharing ICU patients rather than 
full engagement and thorough information exchange across disciplines (Daly et al., 2016). 
Information and knowledge gaps compromise clinical perceptions, leaving critically ill cancer 
patients vulnerable to subjective opinions regarding patients’ prognoses of cancer patients (Frost, 
Cook, Heyland, & Fowler, 2011; Mohan, Alexander, Garrigues, Arnold, & Barnato, 2010; Uy, 
White, Mohan, Arnold, & Barnato, 2013; Visser, Deliens, & Houttekier, 2014). 
The current state of cancer treatment and improved short-term survival outcomes in acute 
care settings are the catalyst for ensuring objective modes of determining prognoses in the 
oncology population are applied at the bedside. The 21st century ushered in technological and 
biomedical advancements in oncology that date back to the signing of the National Cancer Act 
(NCA) of 1971. Through its legislative edicts, major investments in cancer research have led to 
historic successes in the areas of improved chemotherapies, biotherapeutic developments, 
imaging technology, and enhanced side effect management (Conway, Carragher, & Timpson, 
2014; Gambhir, 2002; Ozols et al., 2007; Tiwari & Roy, 2012; Vogelzang et al., 2012; 
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Weissleder, 2006; Wingo et al., 2003). Some patients diagnosed with cancer can now expect 
favorable prognoses amid serious disease and treatment-related complications requiring intensive 
care management (Schellongowski et al., 2004; Torres et al., 2016). 
Investigation into improving the accuracy of prognostic information is warranted to 
reduce the subjective nature of perceived poor outcomes at the bedside (Hall, 2017). Relying 
solely on subjective notions to discriminate between favorable and unfavorable prognoses early 
into the admission process have not proven to be precise among critical care nurses and 
physicians (Detsky et al., 2017; Hall, 2017). Outcomes from studies examining predictive 
prognostic accuracy and concordance between critical care nurses and physicians revealed low 
accuracy rates and discordance between disciplines (Detsky et al., 2017; Neville et al., 2015). 
Acquisition of models that accurately discriminate prognosis remain promising. When applied 
appropriately, prognostic models can contribute important analytical information to guide the 
clinical care of patients (Detsky et al., 2017; Liu et al., 2015; Sawicka, Owczuk, Wujtewicz, & 
Wujtewicz, 2014). 
Several validated prognostic models (vPMs) are readily available for use in the ICU to 
predict short-term mortality risk (i.e., 30-day ICU stay). Three of the most widely used vPMs in 
the critical care environment are the Acute Physiology and Chronic Health Evaluation II 
(APACHE II), Simplified Acute Physiology Score II (SAPS II) and Sequential Organ Failure 
Assessment (SOFA) (Vincent & Moreno, 2010). The vPMs may be utilized to provide 
information for determining acuity of care among critically ill patients, make nurse-patient 
assignments, and support patient-family decisions about care. To-date, APACHE II, SAPS II, 
and SOFA perform well when discriminating between likely survivors and non-survivors in 
general ICU patient populations (Horster et al., 2012; Keegan, & Soares, 2016; Vincent & 
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Moreno, 2010). A knowledge gap exists about how well vPMs perform in critically ill ICU 
cancer sub-populations (Sawicka, Owczuk, Wujtewicz, & Wujtewicz, 2014). Exploring the 
performances of APACHE II, SAPS II, and SOFA among critically ill ICU cancer patients is an 
opportunity to determine utility of these tools to critical care staff at the bedside.  
Purpose Statement 
Performances of APACHE II, SAPS II, and SOFA emerged as objective measures for 
obtaining a prognosis among critically ill ICU patients. Good performance has been established 
for each vPM in general ICU populations, but overall performances in an ICU sub-population, 
such as critically ill cancer patients, have not been established. The primary aim of this study was 
to identify the vPM demonstrating greatest prognostic accuracy in the critically ill adult 
oncology ICU sub-population. To address the primary aim, meta-analysis was performed to test 
pooled results gathered from the best available research. 
The APACHE II, SAPS II, and SOFA models were selected based on established 
validity, objectivity, wide use, and broad acceptance in the critical care medicine domain 
(Vincent & Moreno, 2010). Each model had been studied in several adult general ICU 
populations and ICU sub-populations resulting in the assumption that study-level data would be 
available in the literature. For that reason, measuring the overall performances of APACHE II, 
SAPS II, and SOFA models using a structured, systematic approach to aggregate the findings of 
published literature was determined to be the best approach to meeting the study purpose.  
Prognostic model performance research commonly includes univariate analysis of 
variables (e.g., covariates) being tested for a relationship to ICU mortality. Covariates are 
prognostic indices not captured in the model of interest but determined to be independent 
outcome determinants of 30-day ICU mortality and/or influence the predictive accuracy of vPMs 
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(Ramsey et al., 2008). Each vPM aggregates several, though slightly different, physiological 
variables to determine mortality risk. Examples of physiological variables not included in any 
vPM algorithms but well-established as indicators of cancer-related mortality outcomes include 
the patient “performance status” score at the time of ICU admission, serum albumin level, and 
hydration status (Li et al., 2017; Nwosu et al., 2016; Wolf et al., 2016). Therefore, the secondary 
aim was to describe covariates reported as independent predictors of 30-day ICU mortality.  
Background 
The topic of vPM application is broad and discussion of significance in the oncology 
population is multifaceted. When considering the complexity of cancer patients admitted to the 
ICU, advances in life-sustaining technology, and changing societal expectations for recovery, 
accurate prognostication in the ICU becomes emotionally charged and challenging for critical 
care staff (McDermid & Bagshaw, 2009). Despite the heterogeneity of oncology patients 
admitted to the ICU, biases against aggressively treating critically ill cancer patients, in general, 
persist in this setting and creates ethical concerns. Conversely, patients and/or families may 
request aggressive measures even when care is futile. It is within this context that the predictive 
accuracy of vPMs has a distinct role to play in the relationship between 30-day intensive care 
mortality and cancer-specific prognosis in the ICU.  
Prognostic Models  
General validated prognostic models (vPMs) are tools that offer a systemized way of 
aggregating physiological variables known to be predictors of survival outcomes in the ICU. For 
the purpose of conducting a meta-analysis, this study was limited to three vPMs: APACHE II, 
SAPS II, and SOFA. As generic prognostic systems, the information yielded by each vPM is 
used to establish 30-day ICU mortality risk among critically ill patient groups (Yu et al., 2014). 
5 
 
Mortality risk is quantified using the values of a set of physiological variables routinely observed 
and measured in the ICU by critical care nursing and physician staff. Each physiological variable 
used in a given vPM to generate a prognosis, is measured via ICU-based hemodynamic 
monitoring apparatuses and laboratory specimens (e.g., serum calcium and potassium). These 
same variables are reported regularly in critical care nursing documentation; thus, simplifying 
the steps needed to generate a prognosis at the bedside. 
Every vPM performs statistical calculations to produce a raw severity-of-illness (SOI) 
score and corresponding estimated mortality reported in the form of a percentage. Although the 
bedside nurse collects and documents the information needed in the medical record, either 
critical care nurses (CCNs) or intensivists enter the data into a vPM calculator for a mortality 
probability estimate. A physician then interprets the SOI score and percentage by translating 
these integers into clinical meaningful information. The information gathering and sharing 
process among the nurse-physician teams makes providing a prognosis to patients/families a 
collaborative process between CCNs and intensivists.  
The calculation (SOI score and percentage of estimated mortality risk) is translated into 
terms most appropriate for patient/family levels of education and comprehension. As a 
stipulation, these systems were validated based on measurements obtained within the first 24-
hours of admission for their hypothesized predictive accuracy and must be applied in the same 
manner. As a result, the worst values observed within the first 24 hours are used for baseline 
assessments of patient 30-day survival chances as well as determining baseline prognoses (i.e., 
favorable versus unfavorable).  
The function of vPM calculations resulting in SOI scores are based on vital sign 
measurements and laboratory values of selected physiological variables specified per prognostic 
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system to predict mortality risk. Values of physiological variables (e.g., serum electrolytes, white 
blood cells, arterial blood gases, Glasgow coma scale) included in each vPM are weighted 
according to their known relative impact on 30-day ICU mortality (Vincent & Moreno, 2010). 
Although the physiological variables, along with importance of their corresponding values, 
reasonably vary from one prognostic scoring system to the next, each model combines their 
values for analysis using logistic regression techniques and equations (Vincent & Moreno, 2010). 
Specifically, multiple logistic regression is used in each vPM to provide the probability of 30-
day ICU mortality (Vincent & Moreno, 2010). As a result, vPMs are established objective tools 
capable of stratifying patients into groups in relation to benefit/non-benefit of aggressive care 
measures when admitted into the ICU (Leung, McArdle, & Wong, 2011). 
Cancer Patients in the ICU 
Advances in the delivery of care outside of oncology specialization and the use of life-
saving strategies in the acute care setting contribute significantly to the increase in short-term 
survival outcomes in the ICU. The critical care environment is where specialized knowledge and 
the actions of non-oncology nurse-physician teams make use of advancements in life-saving 
strategies that greatly impact 30-day mortality for critically ill persons. This setting was of 
interest in this study because the number of patients with hematological malignancies and solid 
tumors admitted to this environment has increased (Torres et al., 2016). Past studies report 
improved survival outcomes in several subsets of this patient population while no differences in 
survival outcomes among critically ill cancer patients were observed when compared to general 
critical care patient mixes (Benoit et al., 2003; Torres et al., 2016). 
Similar to the general ICU population, patients admitted to the ICU with a cancer 
diagnosis have situational needs. For example, treatment-related effects due to anti-cancer agents 
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(e.g., sepsis, renal toxicity, coagulopathy) can be very serious yet reversible when timely, 
thoughtful management approaches are delivered in intensive care settings (Parakh et al., 2014). 
Prognosis related to severe insult to health because of treatment is distinctively different from a 
cancer prognosis; rather, prospects of recovery are associated with the severity of 
complication(s) from treatment and how adverse events can be managed best in intensive care 
environments. In addition, certain cancer types are very aggressive at the time of diagnosis and 
respond well to treatment, but carry a poor prognosis when left untreated. For example, a disease 
such as acute promyelocytic leukemia is very aggressive and deadly but “curable”. However, it 
requires appropriate drug combinations administered to a patient under close monitoring 
conditions most conducive to ICU care practices (Rowland et al., 2013; Walker & Held-
Warmkessler, 2010).  
Some cancer treatments, such as immunotherapy administered for malignant melanoma 
requires meticulous nurse monitoring due to life threatening side effects (Yu & Si, 2017). The 
nurse-to-patient ratio and nursing skill levels unique to the ICU environment are supportive of 
rigorous patient care needs. Therefore, the critical care nursing staff is readily available to 
identify serious side effects associated with immunotherapy and facilitate timely care.  In this 
situation, the cancer prognosis is poor due to aggressivenessof disease, while the intent of 
successful treatment is “cure”. Because the physiological demand on the patient is great, ability 
to tolerate therapy is very challenging, and individual response varies; therefore, improved 
prognosis is not guaranteed with this type of treatment (Lefebvre et al., 2017).  
There are case scenarios more clearly indicative of unfavorable prognosis such as cancer 
patients with disease states that are terminal. Terminal illness and poor prognosis are clearly 
established when cancer is no longer responding to available treatments and life-sustaining 
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strategies in the ICU are ineffective. Physiological processes are overwhelmed, health continues 
to decline, and death is imminent with absolute certainty. In this case, a patient receives a poor 
prognosis most befitting of a deteriorating condition and continued efforts to sustain life are 
reasonably futile.  
On the other hand, there are patients with a cancer diagnosis admitted post-operatively 
with complications related to surgery who recover well. In this scenario, both the cancer 
prognosis and 30-day ICU prognosis can be favorable. Moreover, if a post-op patient with cancer 
suffers from a life threatening condition unrelated to the malignancy, it is the 30-day ICU 
prognosis that is unfavorable. The impetus for exploring the different needs of cancer patients in 
the ICU is to establish that prognoses ought to be tailored around the immediate acute 
physiological needs and ICU-specific diagnoses of patients, rather than conditioned beliefs about 
delivering care perceived to be futile. Nevertheless, proficient, high acuity care delivered by 
nursing and medical staff in the ICU makes it the setting best suited for accessing optimum 
nursing care so that critically ill cancer patients have the best chances of survival. 
Significance 
Patient–Family Centered Experience 
Patient ICU experience and family presence at the bedside is a demanding psychological 
event for both (Bolton, 2016; Nikayin et al., 2016). The experience, for patients and family 
members, takes place within an environment of high-tech monitoring apparatuses, alarms, and 
procedures. Studies revealed a lack of emotional support, poor communication, and failure to 
explain prognosis lead to unknowns that create anxiety, psychological distress, and low 
satisfaction with care for both patients and family members (Beckstrand, Lamoreaux, Luthy, & 
Macintosh, 2017; Carlson et al., 2015). The significance of identifying a vPM most predictive of 
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mortality outcomes in the oncology population is its use as a decision aid to offer emotional 
support, communicate health status, and explain prognosis. 
As decision aids, vPMs use physiological variables to assess severity-of-illness to 
generate SOI scores so that these clinical factors are transformed into an “estimated-risk of 
mortality” or prognosis.  Using hemodynamic parameters and physiological characteristics of the 
patient introduces objectivity into clinical reasoning and decision-making so that the patient and 
family have practical information to make decisions. Observations of hemodynamic monitoring 
and nursing care become contextual for patients and family members when staff explain how 
prognosis is clinically derived from the information collected. Patient and family observers 
believe conclusions are more objective when prognoses appear competently integrated into 
bedside care and communication (Zier et al., 2008). 
Sensitivity to staff presence by patients and families is heightened by a sense of 
vulnerability and awareness of mortality. Mortality becomes deeply reflective for patients and 
chance of survival is a focal point of patient/family discourse and decision-making (Hutchison et 
al., 2016). Information sharing regarding prognosis and demonstrations of competence build trust 
between the nurse, physician and patient-family relationship triad (Carlson et al., 2015; 
Hutchison et al., 2016). According to Hutchison et al. (2016), establishing trust early is 
paramount to limiting conflict that can occur during the care planning process between clinicians 
and patients or their surrogate decision makers when prognoses is not fully understood. 
Discordant prognostic estimates from multiple critical care staff cause patients and/or 
family members to experience doubt, mistrust, and frustration (White, Engelberg, Wenrich, Lo, 
& Curtis, 2010; White et al., 2016; Ziers et al., 2012). The importance of establishing vPM 
performance is to have an objective tool for use as a resource to support predicting prognoses 
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amidst questionable outcomes and uncertainty. A thoughtful approach by the critical care staff is 
essential to managing expectations, particularly when clinical judgment is antithetical to 
patient/family beliefs and desires (Ziers et al., 2012).  
Moreover, communicating accurate information, such as SOI scores and estimated 
mortality risk, are important to allaying concerns patients and families have at a time of critical 
illness; however, it must be framed in understandable terms to be meaningful (Gigerenzer & 
Edwards, 2003; White et al., 2016). The value of vPMs is best realized when the complexities of 
a patient condition are translated into relatable terms by critical care staff that address knowledge 
deficits and promote realistic expectations at the bedside (Gigerenzer & Edwards, 2003).   
Prognosis in the Nursing Process 
  Admission to the ICU is associated with mortality; however, prognosis and related goals 
of care are often excluded from the discussion (Hall, 2017; Turnbull et al., 2014).  Nursing 
research indicates CCNs have concerns about the need to take an active role in communicating 
with patients, families, and physicians the significance of prognosis and setting goals of care 
reflective of pragmatic approaches to its related health outcomes (Milic et al., 2015). 
Establishing a prognosis early into the care process helps CCNs identify role expectations and 
navigate patient/family expectations during the nursing care process. 
Although the bedside nurse does not formulate a prognosis, understanding its relevance 
in the care process promotes the delivery of quality care. The nursing process is central to quality 
patient care and applied holistically at the bedside to ensure patient well-being. In the assessment 
phase, the CCN assesses patient and family understanding of prognosis and its relation to setting 
goals of care. Clinical judgment is exercised to recognize knowledge deficits associated with 
patient prognosis in the diagnosis phase. Determining approaches to patient and family 
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information needs are then established in the care planning phase of care. Implementation phase 
involves eliciting physician perspectives on prognosis, orchestrating a family meeting with key 
stakeholders, and providing emotional support.  
Overall, the nursing process requires assessing and developing a care plan addressing 
patient and family perspectives such as, knowledge deficits, fears, desires, and expectations 
about treatments and benefits to health. Nurses are advocates ensuring patients and families 
understand the care process and communication remains an open exchange for asking questions 
and verbalizing concerns.  A prognosis is explained within the context of individual needs, 
educational level, understanding, and preferences (Parker et al., 2007). Throughout the care 
process, the bedside nurse supports patients and families wanting aggressive measures employed, 
despite unfavorable prognoses. The bedside nurse also supports patients with favorable 
prognoses who decline certain aggressive measures that would reverse untoward health issues. 
The process is circular whereby the bedside nurse re-assesses the situation, exercises clinical 
judgment, modifies the plan if needed, acts on cues from patient and family, and revisits goals of 
care. 
Remaining respectful of preferences and values is key to maintaining quality nursing care 
regardless of diverging or converging decisions in response to prognosis-related information. 
Regardless of patient and family attitude towards making major health care decisions, 
appropriate nursing and medical management requires careful assessment of the situation. 
Turnbull et al. (2015) stated that intensivists are reluctant to discuss outcomes for critically ill 
patients in the face of prognostic uncertainty and frequently do not ask surrogates about patient 
values. In response, a component of nursing care is ensuring the environment is conducive to 
discussions centered on prognosis so that the patient and family experience resolution of 
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concerns about health-related unknowns. It is through nurse-physician shared understandings of 
prognosis and clinical value that patient well-being remains at the center of decision quality.  
Theoretical Underpinning 
The aim of this study was to identify the vPM demonstrating the greatest prognostic 
accuracy in the critically ill oncology population. The performances of APACHE II, SAPS II, 
and SOFA were the primary focus. The performance of each vPM begins with measurements of 
physiological variables routinely recorded in the ICU. For each model, a mathematical 
computation is performed using physiological measurements to generate a raw score translated 
into an estimated risk profile. The estimated risk profile is objective information used in 
conjunction with clinical reasoning to communicate a prognosis to patients and surrogate 
decision-makers. 
To explain vPM performance at the bedside, a derived Prognostic Framework (Figure 1), 
built on the underpinnings of three theories, guided the study. The borrowing of theoretical 
principles collectively describe vPM function (principles of physiology and homeostasis), vPM 
validity (Bayes reasoning) and vPM objectivity (Sociological Theory of Objectivity) to generate 
a prognosis in this study. Principles of physiology explain how measurable physiological 
variables serve as predictors of mortality. Biostatistics modeling is the logic applied to 
probability testing (conditional probabilities) and estimates of mortality when physiological 
predictors are aggregated using mathematical computations. Probabilities lead to estimates 
converted into mortality risks to provide objective information about prognosis.  All together, 
each component affects the ability of the model to provide an accurate estimate of ICU mortality 
and justify bedside application for individual cancer patients. That is, probability testing applied 
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to human physiological responses to disease can result in objective information such as 30-day 
ICU mortality risk. 
Homeostasis 
Each prognostic model uses physiological variables representative of well-functioning 
homeostatic control in the human body. Homeostatic control or homeostasis is the degree in 
which the human body maintains equilibrium in its internal environment (Rizzo, 2016). 
Homeostatic process is the action of physiological mechanisms controlling human bodily 
functions and monitoring conditions within organ systems. Examples of homeostasis include the 
regulation of body temperature, acid-base balance, and electrolyte concentrations despite 
changes in the internal and external environment. Minor fluctuations in normal blood pressure, 
breathing pattern, and heart rate in response to physiological/psychological stress are signs of 
well-functioning homeostasis. 
Through a series of complex relationships between different human body systems, 
physiological processes undergo constant adjustments through negative feedback mechanisms to 
sustain physiological balance (Rizzo, 2016).Therapeutic interventions in the ICU focus on 
measuring and restoring physiological balance. Issues such as critical illness, severe injury, 
and/or prolonged physiological stress can decrease the adaptive capacity of homeostatic function. 
Decreased adaptive function leads to inadequate homeostatic control and weakened 
compensatory mechanisms resulting in increased risk of death. When homeostatic processes fail 
and/or therapeutic measures are ineffective, deterioration of health continues and death is 
inevitable. Accoring to the Progostic Framework, the initial step requires homeostasis data 
collection and input.  
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Bayesian Reasoning 
Bayes reasoning is the logic that says an external reality (e.g., survival) can be predicted 
when propositions (i. e., physiological variables) that capture the independent and external 
reality (states of health) are in place. Bayesian theorem employs a mathematical method based 
on outcomes from previous studies, prior trials, et cetera to determine the likelihood of that 
observation occurring in the future (Berger, 2010; Gelman et al., 2013). It involves the use of 
mathematical calculations to quantify a situation(s) such as critical illness with an uncertain 
outcome(s) (e.g., 30-day ICU survivor versus non-survivor) as a part of scientific inquiry to 
reveal an external reality (e.g., 30-day prognosis) (Berger, 2010; Gelman et al., 2013). By 
objectively quantifying the probability of an event occurring (death), Bayesian reasoning uses 
probabilistic language and computations to coincide with an independent, external reality 
(observed mortality). It is a way to show correlation between a predicted reality based on 
conditional probabilities and observed reality such as 30-day ICU mortality (Barton, Ethier, 
Duvauferrier, & Burgun, 2017).  
The concepts, mathematical language and rules of probability based in Bayesian logic 
provide the framework for making objective predictions and generating objective prognoses 
(Barber, 2012; Gelman et al., 2013). The aim is to reach sensible conclusions amid complicated 
situations like the unpredictable yet complex needs of critically ill cancer patients. Conducting a 
meta-analysis on this subject matter involved Bayesian indicators of performance: area under the 
receiver operating characteristic curve (AUC); discrimination and calibration; predictive 
accuracy; and objectivity (see the “Definition of Terms”) (Barbini, Cevenini, Furini, & Barbini 
2014; Barton et al., 2017; Marufu et al., 2015).  
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When reviewing and synthesizing the literature for meta-analysis of prognostic systems, 
it is important to understand the performance of each vPM within the context of Bayesian 
indicators of performance. The diagnostic performance statistic used to describe the predictive 
accuracy of vPM is the AUC. This statistic represents how well a vPM uses propositional logic 
to assign mortality probabilities to ICU survivors and non-survivors. Predictive performance is 
assigned a probability measure (AUC values between 0 and 1) based on binary classifications 
(sensitivity and specificity testing) generated by aggregating conditional variables (physiological 
parameters) to objectively determine likelihood of an event occurring. In the derived Prognostic 
Framework, Baysian reasoning guides the creation of an objective indicator based on the 
homeostatis data from step one. 
Objectivity 
According to Fuchs Sociological Theory of Objectivity (1997), objectivity is realized 
when outcomes measuring the same phenomenon independently, correlate strongly with each 
other and across repeated measurements by several investigators. In this context, performing a 
meta-analysis is the methodology for making use of a large collection of results gathered from 
individual studies in order to integrate findings to gain a new objective understanding. It is a way 
of viewing things dispassionately so that reproducible observations are accepted, applied and 
communicated as empirical evidence.  
Fuchs (1997) argues objectivity requires the scrupulous and pedantic work of stripping 
away biases and prejudices, as they exist in a profane world. Through a constructivist lens, 
findings that are inconclusive and/or ambiguous, detract from and hamper objectivity. The nature 
of objectivity is uncovered through correspondence between accurate statements (or facts) and 
the external reality. As a product of objective knowledge, a new language evolves out of 
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reproducible observations; hence, the evidence obtained by means of scientific inquiry 
disciplines (hold in control) subjectivity of observations in lieu of arbitrary ideas (Fuchs, 1997). 
In principle, information communicated to the patient-family must be based in the best available 
evidence rather than influencing factors such as mainstream social ideas, norms, beliefs, 
relationships, or statuses (Fuchs, 1997).  
Objectivity is both empirical and a medium of communication (Fuchs, 1997). Analyzing 
the findings from a collection of studies is the conduit for establishing evidence-based 
conversations about vPM function as an objective tool at the bedside and represents the third step 
in the Prognostic Framework. Through the totality of the evidence, carefully made inferences 
will inform and guide clinical utility. That is, objectivity sets the rules of scientific inquiry, 
represents an independent reality and is a hallmark of transferrable impartiality (Fuchs, 1997). 
As a result, the performances of vPMs act as conduits for objectivity, which produce objective 
information for prognosis-related probabilities available to be shared. This process lay at the core 
of this investigation. 
Objectivity in the Nursing Process. Objectivity is an intellectual phenomenon requiring 
inspecting the methods through which knowledge is formed clinically and subsequently reflected 
in professional attitudes and behaviors (Engebretsen, Heggen, Wieringa, & Greenhalgh, 2016). 
Constructing care that is concordant with patient’s wishes and values must start by framing 
prognosis objectively using information inclusive of best and worst-case scenarios to establish 
balance (Hoerger et al., 2013). Objectivity mediates subjective notions, attitudes, beliefs, and 
planned actions. By providing a balanced approach using objective prognostic information, 
professional biases are reduced and patients receive more than one-sided presentations of clinical 
data (Hoerger et al., 2013).  
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Re-conceptualizing ICU survival requires that estimates of prognosis are the result of an 
objective process. Prognosis is a forecast of clinical outcome and its clinical utility is intertwined 
with patient and family understanding and perspective. Consequently, prognosis makes 
objectivity an essential component of clinical reasoning, medical decisions, and nursing actions 
because of risk of harm to the patient (e.g., withholding care when benefit outweighs risk) (Zier 
et al., 2008; Zier et al., 2012). Nurses and physicians must deliver impartial care and equip 
patients and family members making treatment decisions with accurate information essential to 
making value-based decisions regarding treatment (Dugas et al., 2017). 
Moreover, nurses use aspects of prognosis to explain evidence-based rationale for care 
and to be patient advocates while physicians rely on prognosis to justify treatment 
recommendations. Engebretsen et al. (2016) noted that empirical objectivity is the scientific 
approach to asking, “Did I observe and/or imagine the situation in the right way?” Objectivity 
and tools that help clinicians objectively determine probability of mortality is a way of reducing 
the subjectivity in clinical observations (i.e., predicting short-term prognoses). From this 
position, objective knowledge is important when subjective views are antithetical to the reality of 
either favorable or unfavorable short-term outcomes in the ICU.  
Research Questions 
  The primary aim of this study was to answer the question, “Which prognostic scoring 
system performs 30-day mortality predictions most accurately for critically ill cancer patients 
admitted to the ICU?” Once identified, the tool with optimal performance can subsequently serve 
as the model that augments CCN views and advocacy at the bedside as well as inform clinician 
perceptions, clinical judgment and treatment recommendations. Essentially, the focus was 
identifying performances of vPMs as a source of objectivity for later use to inform nurse 
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knowledge and actions as well as physician-based clinical reasoning, which leads to information 
sharing with patients and families when appropriate. 
  Overall, the objectivity of the outcome serves as evidence for conversations about the use 
of vPMs in reducing the subjective nature of both nurse and physician perceptions about patients 
with a cancer diagnosis in the ICU. Evidence generated from this meta-analysis to answer the 
research question was a way of identifying a vPM that can be used to build concordance between 
nurse-physician perspectives at the bedside and application to decision support for patients and 
families. Because of the availability of three vPMs, the choice of an objective tool offers the 
impartiality needed when sharing prognosis-related information with patients and families during 
the shared decision-making process.  
  The secondary aim was to answer the question, “Among the study sample, what 
physiological variables are reported to be additional independent predictors of 30-day mortality 
for oncology patients in the ICU?” By answering this question, clinicians can use the findings to 
expand clinical knowledge regarding the degree of influence adjunctive physiological variables, 
not captured in the models, play in SOI scores and estimating risk of 30-day ICU mortality. The 
answers to both the primary and secondary questions contextualize the use of prognostic scoring 
systems in critically ill oncology populations. The findings are expected to help CCNs better 
understand the role of vPM use at the bedside and specific application to the care of oncology 
patients. For both CCNs and intensivists, the discussion of findings should expand professional 
knowledge of vPM value to the diversity of ICU patients and how futile care are perceived to 
healthcare professionals at the bedside.  
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Definition of Terms 
 Conducting a meta-analysis centered on the performance outcomes of ICU-based 
predictive tools and explaining the statistical methodology involves understanding the meaning 
of Bayesian terminology. Key terms are defined as follows. 
Area under the ROC curve (AUC). Area under the curve measures the correlation 
between the category predicted by the test and the true category into which the case falls 
and how often predictions and outcomes are concordant (Gonen, 2007; Munro, 2005). 
The closer the AUC is to 1.0 (e.g., 0.80) the better the performance of prognostic model 
is at making accurate predictions. For example, an AUC value of 1.0 means the test is 
perfectly accurate. The practical lower limit for the AUC of a diagnostic test is 0.5 
(Gonen, 2007). 
Calibration. Calibration is the degree of agreement between a model’s predicted 
probabilities and true (or observed) probabilities using general linear model (GLM). 
Cohort.  A cohort is a group of subjects sharing a defining characteristic particularly, 
patients grouped according to the vPM model used to predict mortality. 
Discrimination. Discrimination is the degree to which a probability model is able to 
distinguish between survivors and non-survivors within a 30-day interval (Afessa, 
Tefferi, Dunn, Litzow, & Peters, 2003; den Boer, de Keizer, & de Jonge, 2005).  
Performance. In this study, performance refers to a statistical expression reflecting the 
degree of concordance between predicted outcome and observed outcome (den Boer, de 
Keizer, & de Jonge, 2005; Gonen, 2007). 
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Predictive accuracy.  Predictive accuracay is a statistical phrase referring to a 
calculation of the probability that the test result and prediction agree; the overall 
precision of a test in measuring true findings. (Munro, 2005). 
Summary 
Scientific advancements in recent years have resulted in better treatment protocols, 
greater cure rates and declining mortality rates within the cancer population (NCI, 2015a; NCI, 
2015b; Ryerson et al., 2016; Siegel, Miller, & Jemal, 2015). Despite improvements in treatment 
approaches and supportive care measures, there are instances when patients with active cancer 
diagnoses require care most befitting in the ICU. The heterogeneity of the critically ill cancer 
population and varying nature of disease (i.e., curability, reversibility, control, or terminal) 
makes broad negative assumptions about ICU survival inappropriate. Although the risk of 
delivering futile care is a legitimate concern in the ICU, the extent of medical intervention cannot 
be determined by diagnosis of cancer alone. This reality requires ICU survival be re-
conceptualized because of diversity in clinical presentations, needs, and available resources to 
manage critical illness. 
Based on research, reluctance among critical care nurses and intensivists to admit 
critically ill cancer patients to the ICU is attributed to fatalistic views and beliefs about poorer 
outcomes associated with an active cancer diagnosis (Bird et al., 2012; Kopterides et al., 2011; 
Neville et al., 2015). In addition, critical care staff have reported experiencing apprehension 
towards delivering costly care that is perceived as having no benefit to 30-day survival in the 
ICU (Bos et al., 2015; Cruz, Camalionte, & Caruso, 2015; Kim et al., 2014; Markou, 
Demopoulou, & Myrianthefs, 2008; Sibbald, Downar, & Hawryluck, 2007). These views persist 
in spite of improved management strategies available to reverse untoward treatment effects, 
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control disease, and restore health. Competing factors (set beliefs and perceptions versus patient 
characteristics and advancements in treatments) cause predicting 30-day ICU mortality to be a 
conundrum for critical care staff in the absence of an objective medium. 
Referencing a prognostic tool is an opportunity to weigh the benefits and risks involved 
in ICU admission without bias when triaging cancer patients (Cavallazzi et al., 2009). While 
seeking to provide fair distribution of available ICU resources during triage decisions, clinical 
inclinations are directed towards ICU patients who are mostly likely to survive if admitted 
(Blanch et al., 2016). Unfortunately, triaging is taking place under conditions by which decisions 
for or against ICU admission of cancer patients are often inappropriately focused on the 
underlying malignant disease rather than the physiological parameters representative of mortality 
outcomes (Blanch et al., 2016; Cavallazzi et al., 2009; Horster et al., 2012).  
Nevertheless, the mathematical probabilities of mortality risk, generated by vPMs, inject 
objectivity early into the ICU stay (applied within first 24 hours of admission). When applied at 
admission, the timing of vPM application addresses the subjectivity of traditional beliefs 
influencing how cancer patients are perceived and concerns about futile care in the early hours of 
admission to the unit. When used appropriately, vPMs function as objective tools that inform 
critical care management, critical care nursing action, and support patients and families 
understanding about the direction of care.  
Appropriate use indicates healthcare professionals acknowledge patient-family 
informational needs. Application also reflects attempts to address anxieties in order to better 
facilitate the decision-making process in response to both favorable and unfavorable prognoses. 
The information derived from vPMs does not replace clinical judgment; rather, vPMs add 
impartial information to clinical reasoning and aid the decision-making process. The intent of 
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vPM use is to reduce variability in perceptions between nurses at the bedside and intensivists so 
that patients and family members receive congruent information from staff (Gaeta & Price, 
2010). By reviewing and analyzing the literature, additional insights about the performance of 
vPMs in the cancer population and identification of variables influencing their predictive 
accuracy broadens the understanding of clinical utility among nursing and medical practice. The 
intent is translatable findings applicable at the bedside. 
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Chapter 2 
Review of the Literature 
Admission to the ICU requires consideration for weighing the benefits of providing 
advanced life sustaining measures against the risk of excessive measures that do not reverse 
physiological insult to health. Employing aggressive treatment approaches that do not result in 
quantifiable or qualitative improvements to patient outcomes (i.e., meaningful survival) is 
perceived by many critical care staff to be futile care (Cruz, Camalionte, & Caruso, 2015; Louie, 
et al., 2013; Mohammed & Peter, 2009; von Gruenigen, & Daly, 2005). Moreover, research has 
shown that ICU clinicians (i.e., intensivists, critical care nurses) continue to reluctantly admit 
severely ill cancer patients to critical care units because of perceptions of poor prognoses, 
concern for excessive consumption of resources, and assumptions of delivering costly care that is 
deemed futile (Bird, Farquhar-Smith, Wigmore, Potter, & Gruber, 2012; Horster et al., 2012; 
Sibbald, Downar, & Hawryluck, 2007).  
Advances in the management of malignancies and complications of treatment resulting in 
improved survival outcomes make traditional views of cancer patients as poor candidates for 
admission to the ICU unjustified (Aygencel, Turkoglu, Turkoz-Sucak, & Benekli, 2014; 
Staudinger et al., 2000). Investigations into ICU mortality among critically ill cancer patients 
reveal that survival outcomes are comparable with severely ill non-cancer patients (Bird et al., 
2012; Ñamendys-Silva et al., 2010; Ñamendys-Silva et al., 2015). Moreover, data demonstrating 
increase survival rates support the need to incorporate objective modes of determining prognosis 
into the care planning process.  
Distinguishing between medical and surgical causes as well as underlying co-morbidities 
adds to the complex nature of clinical observation-derived prognoses. Clinical observations in 
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tandem with negative perceptions and assumptions can distort mortality predictions (Gigerenzer 
& Edwards, 2003; Zier et al., 2012). When outcomes are poorly conceptualized (i.e., 
misperceptions of prognosis), patients and families can potentially be harmed by receiving 
inaccurate information (Gigerenzer & Edwards, 2003; White et al., 2016). In addition, the 
existence of inter-professional discordance in observations along with biases between critical 
care nurses and intensivists tend to breakdown collaborative decision-making efforts (Neville et 
al., 2015; Turnbull et al., 2014). Therefore, objective tools that inform nurse and physician 
assessments of complex, somber issues inherent to the care of critically ill patients have 
prognostic implications for guiding care (Neville et al., 2015). 
While it is important to recognize that patients with an active cancer diagnosis, including 
metastatic disease, now have better chances of survival, uncertainty about surviving a 30-day 
stay in intensive care persists for both patients/families and non-oncology ICU nurses and 
physicians (Huffines et al., 2013; LeBlanc, Kenny, O'Connor, &  Légaré, 2009; Torres et al., 
2016). Thoughts of poor prognoses are not unfounded when examining certain patient situations. 
For example, the uncertainty about a poor prognosis is diminished among patients with well-
established terminal illnesses attributed to advancing malignancy and/or irreversible organ 
failure related to treatment. Through variations and differences in cancer patients needs, clinical 
presentations serve as the impetus for re-conceptualizing ICU cancer survivors and non-
survivors. Prognostic models are the objective approach to mediating clinical judgment when 
patients are at-risk for biased beliefs about delivering futile care and related outcomes. 
Prognosis 
Accurate prognosis in the acute care setting is central to clinical decision-making because 
of its direct relationship to patient outcomes (Mallet et al., 2010). As the endpoint of care, 
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nursing processes and medical approaches involve patient health status, disease characteristics, 
and treatment preferences. Together, these factors and related variables determine patient 
treatment options, inform the direction of care and are influential in predicting short-term 
survival outcomes (e.g., 30-day ICU survival) (Bird, Farquhar-Smith, Wigmore, Potter, & 
Gruber, 2012; Bos et al., 2015). Inclusion of prognosis, timeliness of prognostic information, and 
way of communicating prognosis-related information with patients and/or family decision-
makers, serves as the basis for setting realistic expectations in the ICU (Hutchison et al., 2016; 
LeClaire, Oakes, & Weinert, 2005).  
Favorable and unfavorable prognoses in oncology patients are not always apparent at the 
bedside. Cavallazzi et al. (2009) explained that critically ill patients with malignancies are a 
heterogeneous group with varied prognoses and specific factors have been associated with 
different outcomes. Prognostic tools are a way of deciphering between patients most likely to 
survive and critically ill cancer patients who may not benefit from aggressive treatment 
approaches (Bos et al., 2015; Moons et al., 2009; Suhag et al., 2014). In this instance, the 
subjective nature of biases at the bedside are replaced with objective measurements of mortality 
risk with the use of vPMs. However, discussions about the relationship between prognosis and 
the role of vPMs in allaying concerns about delivering futile care in the oncology population is 
absent from the literature. 
Prognostic Models 
The original development of prognostic models began more than 35 years ago as a means 
to predict the short-term risk of death (30-day ICU mortality) for ICU patient groups (Vincent & 
Moreno, 2010). The Acute Physiology and Chronic Health Evaluation II (APACHE II), 
Simplified Acute Physiology Score II (SAPS II) and Sequential Organ Failure Assessment 
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(SOFA), are among a few general ICU vPMs available for the adult population (i.e, 18 years and 
older). These three vPMs are well-established and most frequently used generic prognostic 
indices reported in the literature (den Boer, de Keizer, & de Jonge, 2005; Tang et al., 2005; 
Vincent & Moreno, 2010). As popular prognostic tools, APACHE II, SAPS II, and SOFA are 
readily available online and in the format of “apps” downloaded to personal computers and 
mobile devices (e.g., Smartphone, tablet computer) at no cost or via subscription to individual 
users, institutions, and hospital systems. The requirements of use for each vPM are limited to 
entering the value of the specified physiological variables (e.g., age, hematocrit, temperature) for 
statistical computation similar to a calculator.  
The collection of physiological variables for APACHE, SAPS, and SOFA were selected 
by way of expert consensus, weighted for mortality prediction through use of statistical modeling 
techniques, with estimated risk established using multiple logistic regression models (Knaus, 
Draper, Wagner, & Zimmerman, 1985; LeGall, Lemeshow, & Saulnier, 1993; Vincent et al., 
1996). The overall aim was to quantify the natural disease process within the context of 
therapeutic interventions based on objective criteria. This led to the selection of certain 
physiological variables routinely measured in the ICU and managed therapeutically in response 
to clinical aberrations (see Appendix A). These are the combined physiological variables 
contained in all three vPMs. 
Based on the principles of homeostasis, each physiological variable used in a model is an 
independent predictor of survival outcome. For example, variables representing poor kidney 
function (creatinine > 4mg/dl), compromised immunity (white blood cells [WBC] < 2.0), and 
severe respiratory failure (partial pressure of oxygen [PaO2] <80 mm Hg), are signs of 
homeostatic imbalances driving critical illness and influencing survival outcomes. For clinical 
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feasibility purposes, particular considerations were given to common variables measured in the 
ICU that capture homeostatic disequilibrium. Physiological factors like blood pressure, platelets, 
fraction of inspired oxygen (FiO2), arterial acidity (pH), serum bicarbonate and bilirubin, are 
accessible in intensive care settings yet objective measurements of physiological health. 
 Because of the unique characteristics of care in the ICU, conditions of care such as 
whether or not a patient is receiving mechanical ventilation and use of vasopressors are also 
included in models’ formulae. Specific to model design concerns, focus was directed at simple 
and practical applications at the bedside for all three vPMs. To promote use, clinical 
practicability involved interventions that did not go beyond usual activities performed regularly 
by CCNs and intensivists. For example, the neurological component of the vPMs relies on the 
Glasgow Coma Scale (GCS) routinely performed by the bedside nurse. This led to reasonable 
steps to generate mortality risk predictions that are documented with simplicity in the ICU 
medical record, communicated among healthcare professionals, and shared with patients and 
families.  
The limitation of vPM use entails every field being accurately populated to produce a 
SOI score and corresponding percentage of estimated mortality risk (e.g., SAPS II total score = 
72 points with estimated mortality 86%). Patient needs must align with the physiological 
parameters of the vPMs for clinical usefulness. Appropriate use requires physicians to order 
laboratory values, particularly, a basic metabolic panel (BMP), complete blood count (CBC), and 
bilirubin. In addition, the CCN must receive orders for cardio-respiratory monitoring (including 
arterial blood gases [ABGs]). Missing data interferes with complete assessment of prognosis; 
therefore, calculations cannot be performed.  
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Over time, newer versions of original models (i.e., APACHE to APACHE II and SAPS to 
SAPS II) have been adapted to accommodate changing patient demographics, disease 
prevalence, and advancements in intensive care practices. Because of these factors and 
substantial variations in SOI across different ICU populations, vPMs apply case mix adjustments 
to statistical formulations and estimates (Livingston et al., 2000). That is, each prognostic model 
performs statistical procedures to permit comparison of outcomes between providers with 
differing mix of ICU patients, which allows for validation across multi-unit/site/geographical 
locations. The development of each vPM takes into consideration broad implications for ICU 
admission and contributing factors influencing the probability of change in the outcome measure 
(30-day survivor versus non-survivor) as a means for accommodating heterogeneity in the ICU 
population (Pappachan, Millar, Bennett, & Smith, 1999).  
As stated earlier, vPMs rely on the aggregation of worst values of physiological factors 
(case mix variables) captured within the first 24 hours of admission. These factors are combined 
to generate a score that is predictive of ICU-based mortality for each patient. The raw scores are 
stratified into prognostic indices with higher scores strongly correlating with mortality. Using the 
rule of general linear model (GLM), the score at time 1 (< 24 hours) is considered the strongest 
predictor of outcomes due to regression artifacts (Campbell, 1996). Consequently, the raw score 
(based on worst values) is included in the prediction model for estimating 30-day ICU mortality. 
Repeated measurements beyond the initial 24-hr monitoring period have not shown to improve 
vPMs’ predictive accuracy (Ferreira et al., 2001; Ho et al., 2007; Minne, Abu-Hanna, & de 
Jonge, 2008). 
The reliability and validation (criterion-related and external validity) of each vPMs’ 
performance (predictive accuracy) are based upon “discrimination” and “calibration” (Keegan & 
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Soares, 2016). Discrimination refers to a model’s ability to make predictions by differentiating 
between 30-day ICU survivors and 30-day ICU non-survivors with accuracy. It is reported using 
the area under receiver operating characteristic curve (AUC) which is expressed in the form of a 
correlation coefficent ranging from 0 to 1 and displayed via a GLM graph.  
Discrimination quantifies the accuracy of predictions whereby perfect accuracy is 
equivalent to an AUC of 1. An AUC closer to 0 is indicative of poor discrimination (e.g., AUC 
0.35). For example, a prognostic model predicted 75% mortality within a sample of 100 patients 
and 75% of the patients died, the AUC will be 1. However, an AUC of .5 indicates the model 
prediction is equivalent to chance (Keegan & Soares, 2016). It is also another way of describing 
sensitivity and specificity (i.e., true positive and true negative cases) within the context of 
prognostic tools. Sensitivity and specificity testing is used to form the receiver operating 
characteristic curve (ROC) and AUC is the product of sensitivity and specificity results. 
Table 1 shows the parameters of the scale. The scale ranges from 0 to 1 with 0.5 equivalent to 
chance. For the scale to be meaningful in the clinical setting, it must perform at 0.7 or better. 
Table 1. 
Classifying Predictive Accuracy of a Prognostic Test* 
Performance Range Rating Grade 
.90 – 1 Excellent  A 
.80 – .89  Good B 
.70 – .79 Fair C 
.60 – .69 Poor D 
.50 – .59 Fail F 
*Reference ranges retrieved from den Boer, S., de Keizer, N. F., & de Jonge, E. (2005). Performance of prognostic models in critically ill cancer 
patients - a review. Critical Care, 9(4), R458-463. https://dx.doi.org/10.1186/cc3765  
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As a complement to discrimination, calibration is the degree of agreement between a 
model’s predicted probabilities and true (or observed) probabilities using GLM. It answers the 
question, “Are the predictions of the model reliable?” (Vergouwe, Steyerberg, Eijkemans, & 
Habbema, 2002). Calibration is reported statistically using the Hosmer-Lemeshow (H-L) 
goodness-of-fit test, which gives a chi-square statistic (den Boer, de Keizer, & de Jonge, 2005). 
When the H-L yields a p value greater than 0.05, it is an implication of good calibration while 
small p values (high H-L statistics) indicate lack of fit (Dreiseitl & Osl, 2012; Hosmer, Hosmer, 
Le Cessie, & Lemeshow, 1997; Vergouwe et al., 2002). When reviewing the literature centered 
on the performance of prognostic models, authors must report discrimination and calibration to 
establish validation of vPMs within the respective studies. 
External validity is strengthened when study settings include different ICUs, institutions, 
and/or countries. Mixed populations also expand models’ generalizability when good 
discrimination and validation are achieved under scientific rigor. When reviewing the literature, 
the aim is to identify validation studies with large samples, diverse populations, multi-sites, and 
varying geographical locations to establish validation of vPMs that will be used to answer the 
primary research question. For the aforementioned reasons, APACHE II, SAPS II, and SOFA 
were presumed to fit the criterion resulting in these models being the focus of the literature 
review. 
APACHE II in the Literature 
The Acute Physiology and Chronic Health Evaluation II (APACHE II) is most widely 
used among prognostic systems around the globe; thus, making it the default gold standard for 
assessing disease severity on admission to the ICU and formulating outcome predictions (Knaus, 
2002; Tang et al., 2005). It currently uses 12 physiological variables and incorporates immuno-
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compromised status into its probability prediction (see Appendix B). The score ranges from 0 to 
71 with a score of 60 points equaling an estimated mortality of 99.5% as well as a score of 30 
and 15 correlating with 75% and 25% risk of mortality, respectively (see Table 2).   
 
The APACHE  prototype was developed in 1981, tested in two ICU settings (a university 
and community hospital) and validated with 805 patients (Knaus et al., 1981). This original 
version contained 34 physiologic variables with an increase in score closely correlating with 30-
day ICU mortality. The model was then revised 4 years later, in 1985 (APACHE II), to simplify 
use and increase clinical utility while maintaining the statistical accuracy of the model (Knaus, 
Draper, Wagner, & Zimmerman, 1985). As a multi-institutional validation study, researchers 
applied APACHE II in 13 mixed medical-surgical ICUs in the United States. This follow-up 
study was conducted prospectively between 1979 and 1982 with an enrollment of 5,815 patients 
(admitted for post-operative, non-operative, emergency, and/or severe chronic conditions 
monitoring); patients with cancer were included (Knaus, Draper, Wagner, & Zimmerman, 1985). 
Specifically, all 13 hospitals had a percentage of cancer patients in the study that ranged from 1-
11% (Knaus et al., 1985). 
Table 2.  
Acute Physiology and Chronic Health Evaluation II*  
*Publically available at: https://www.mdcalc.com/apache-ii-score 
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Both the developmental and validation studies established APACHE II’s clinical validity 
after it was found to have both good discrimination (> 0.8) and calibration (p > .05) as well as 
generalizable to the ICU population-at-large (Knaus et al., 1981; Knaus et al., 1985). To date, the 
APACHE II continues to be used and its performance studied worldwide in general and selects 
ICU patient mixes that include multi-center locations (Livingston et al., 2000, n = 10,393; Nobile 
et al., 2016, n = 469; Vassar et al., 1999, n = 2,414). As the perceived gold standard among 
vPMs, researchers have sought its appropriateness for application in high mortality risk groups.  
High-risk ICU sub-groups identified in the literature were diverse. Model performance 
among patients with cancer showed good discrimination (Chang et al., 2006, n = 1,263, AUC 
0.86, H-L p = 0.58 ). Model performance among patients with cardiac disease was also good 
(Argyriou et al., 2015, n = 300, AUC 0.84, H-L p = 0.15).  When APACHE II was applied to 
trauma patients (Hwang et al., 2012, n = 706, AUC 0.95, H-L p = 0.3), those with various 
infections (Williams et al., 2016, n = 8,871, AUC 0.90, H-L p = 0.53), and pulmonary embolism 
(Chen et al., 2017; n = 55,967, AUC 0.923, H-L p 0.23), it showed excellent discrimination. The 
ability of APACHE II to discriminate among end stage liver disease patients (Wernly et al., 
2017, n = 4,381, AUC 0.76; H-L not reported), cirrhosis (McPhail et al., 2015, n = 971, AUC 
0.768, H-L p = 0.78), cerebral hemorrhage (Huang et al, 2016, n = 546, AUC 0.76, H-L 0.84); 
after in-hospital cardiac arrest (Senaratne & Veenith, 2015, n = 261, AUC 0.706, H-L not 
reported) and individuals over the age of 90 (Haq et al., 2014, n = 951, AUC 0.74, H-L not 
stated), proved to be less accurate with predicting mortality among the groups studied. 
Some validation studies focusing on sub-groups did not include goodness-of-fit tests 
results. This limited the ability to accept validation solely based on a model’s discrimination 
(reporting AUCs) in those studies. When compared to other generic vPMs (e.g., SAPS II, SOFA) 
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using both prospective and retrospective study designs, the results have shown good and 
comparable discriminative ability for predicting outcomes but APACHE II did not always 
emerge as the superior performing model (Livingston et al., 2000; Nobile et al., 2016; Vassar et 
al., 1999). Mixed results were identified in APACHE II validation studies centered on cancer 
patients making it a challenge to establish it as a superior performing prognostic tool in this 
population (Afessa et al., 2003; Benoit et al., 2003; Berghmans et al.,2004; Schellongowki et al., 
2004; Sculier et al., 2000; Soares et al., 2004).  
Lastly, the literature review included a search for systematic reviews. Only one of the 
three systematic reviews identified discussed oncology patients. In this study, APACHE II 
performance was compared with five other models (including SAPS II but not SOFA) in the 
critically-ill cancer population (den Boer, de Keizer, & de Jonge, 2005).  Among the 10 articles 
reviewed, only six included APACHE II. The authors surmised that large study design variations 
made it difficult to perform meaningful comparisons (den Boer et al., 2005). Because of these 
findings, the optimal performance of APACHE II in the oncology sub-population remained 
unknown. 
SAPS II in the Literature 
The Simplified Acute Physiology Score (SAPS) is a validated tool that uses 14 
physiological variables for its statistical formulation, which produces a raw score. It also 
incorporates “age”, “type of admission” (scheduled surgical, unscheduled surgical, or medical), 
and the presence or absence of three underlying disease variables (acquired immunodeficiency 
syndrome, metastatic cancer, and hematologic malignancy) into its statistical equation (see 
Appendix C). The score ranges from 0 to 163 points with a score of 52 points corresponding with 
50% mortality, 64 points equaling an estimated mortality of 75% while 77 points yields an 
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estimated 90% mortality risk (see Table 3). The reliance on continuous variables and categorical 
variables to devise mortality predictions is the reasoning for GLM statistical approach. 
 
  It was initially developed in 1984 and applied in eight ICUs with 679 patients 
participating (Le Gall et al., 1984). It then underwent revision (SAPS II) in 1991and 1992 to 
refine its probability calculations for converting a raw score into the probability of in-hospital 
mortality (LeGall, Lemeshow, & Saulnier, 1993). The revised version was developed and 
applied prospectively. The study analyzed the predictive accuracy of SAPS II among 13,152 
patients recruited in 137 medical, surgical, and mixed ICUs from 12 countries (North America 
and Europe) spanning a 3 month period in 1992 (LeGall et al., 1993).  
Each study participant got randomly assigned to the “development” data sample (65%) or 
“validation” data sample (35%). The study excluded patients under the age of 18, those who 
were burn victims, and individuals with coronary care needs (including cardiac surgery) from 
both samples. The patient mix included those with malignancies (solid and hematological) and 
receiving chemotherapy. In the findings, LeGall, Lemeshow, and Saulnier (1993) reported good 
discrimination (AUC 0.88) and calibration (H-L p = 0.883) for the developmental sample. The 
validation sample performed similarly with good discrimination (AUC 0.86) and very well with 
its goodness-of-fit test (p = 0.104).  
Table 3.  
Simplified Acute Physiology Score II*  
*Publically available at: http://clincalc.com/IcuMortality/SAPSII.aspx 
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Since its development, additional validation studies have been conducted to evaluate 
SAPS II performance with other generic vPMs such as comparing it with APACHE II in general 
ICU case mixes (Godinjak et al., 2016). Godinjak et al. (2016) reported good discrimination, 
AUC 0.892 and AUC 0.920, for SAPS II and APACHE II respectively in a sample of 174 
patients. In addition, Pearson’s correlation was used to evaluate the relationship between these 
two vPMs. The researchers found a positive correlation that was statistically significant between 
the values of SAPS II and APACHE II (r = 0.708; p = 0.001). 
 Lemeshow and LeGall (1994) conducted a systematic review to compare prognostic 
tools and determine their clinical usefulness. The authors concluded that the evidence supported 
SAPS II application in assessing prognosis, comparing ICU performance, and stratifying patients 
for clinical trials. Nevertheless, SAP II model performance in the oncology ICU sub-population 
was not discussed. This resulted in an identified gap in the literature and interest in further 
investigation. 
International validation studies exploring the predictive performance of SAPS II were 
also identified in the literature. These studies were conducted inside and outside of the United 
States. Nobile et al. (2016) investigated its clinical validity in 730 ICUs located in 84 countries 
but the sample was small (n = 469 patients) relative to the study design. Livingston, et al. (2000) 
performed a large study in Scotland covering 22 ICUs with 13,291 participants but the 
percentage of cancer patients was not disclosed in the study characteristics or findings. Sakr et al. 
(2008) study was set in a German university hospital with 1,851 patients. In each of these 
validation studies, SAPS II demonstrated the best discrimination in comparison with APACHE II 
but superior calibration over APACHE II was not established. In addition, the investigators did 
not report the distribution of cancer patients. 
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More recently, the performance of SAPS II among ICU sub-groups has also been studied 
to further establish its clinical validity. Outcomes in groups like patients with end stage liver 
disease (Wernly et al., 2017, n = 4,381, AUC 0.78, H-L not stated), cirrhosis (McPhail et al., 
2015, n = 971, AUC 0.781, H-L p = 0.78) and individuals over the age of 90 (Haq et al., 2014, n 
= 951, AUC 0.75, H-L not stated), showed SAPS II performing fair discrimination and good 
calibration when reported. This model also showed excellent discrimination and calibration  
among patients with infectious diseases (Williams et al., 2016, n = 8,871, AUC 0.90, H-L p = 
0.68).  These findings suggest that SAPS II clinical validity and external validation varies among 
sub-groups in the ICU.  
 In the cancer ICU sub-population, SAPS II was matched with APACHE II in patients 
with only hematological malignancies (Benoit et al., 2003) and hematologic/solid tumor case 
mixes (Schellongowki et al., 2004). Benoit et al. (2003) reported fair discrimination for SAPS II 
(AUC 0.77) and APACHE II (0.71) with good calibration, 0.60 and 0.39, respectively. 
Schellongowki et al. (2004) findings showed superior performance for APACHE II (AUC 0.83) 
over SAPS II (AUC 0.78) with good calibration for both (APACHE II = p 0.058; SAPS II = p 
0.066). On the other hand, Sculier et al. (2000) conducted a comparison study that included 
patients with metastatic disease that showed poor discrimination (APACHE II AUC 0.60; SAPS 
II AUC 0.67) and poor calibration (APACHE II p 0.001; SAPS II p 0.001). Collectively, these 
results are mixed resulting in the optimal performance of SAPS II in the oncology population yet 
to be determined. 
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SOFA in the Literature 
The Sequential Organ Failure Assessment (SOFA) is an organ failure based prognostic 
system and an established predictor of mortality in critically ill patients (Akbar, Shahzadi, 
Khurram, & Khar, 2016; Vincent et al., 1996). Differing from APACHE II and SAPS II, the 
SOFA model was created based on the premise that multiple organ failure is a major cause of 
morbidity and mortality in the critically ill patient and can be assessed repeatedly to define a 
patient’s progress (Vincent et al., 1996; Vincent, Ferreira, & Moreno, 2000). Using physiological 
variables representative of six organ systems (lungs, bone marrow, brain, heart, kidney, and 
liver), the SOFA model produces score ranges from 0 to 24 points (see Appendix D). Scores 
closer to 24 are indicative of greater chance of 30-day ICU mortality (see Table 4).  
For example, A score of 12 corresponds with an estimated mortality ranging from 40% to 50% 
versus a score of 17 points equaling an estimated mortality risk  > 90%.  
 
The historical development of the SOFA model began in 1994 with a panel of critical 
care medicine experts. The panel of experts hypothesized that the development of new 
therapeutic interventions aimed at reducing the severity of organ dysfunction in the ICU called 
*Publically available at: http://clincalc.com/IcuMortality/SOFA.aspx 
Table 4.  
Sequential Organ Failure Assessment *  
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for better ways to objectively quantify SOI (Vincent et al., 1996). The group posited that the way 
patients are treated in ICUs as well as therapies used by intensivists to manage organ failure, 
may change over time. Therefore, a model needed to be constructed with deliberation for how 
therapeutic advancements and management strategies influence outcomes. This process required 
a more systematic, objective means for quantifying organ failure to accommodate changing 
paradigms.  
These intentions gave sway to development studies identifying important predictors of 
mortality (i.e., respiratory-, coagulation-, neurological-, cardiovascular-, renal-, and liver-related 
variables). Considerations for treatment response and disease progression were parts of the 
process to successfully establish SOFA’s predictive performance (Vincent et al., 1998; Vincent 
et al, 2000). The actions of model developers subsequently led to validation studies in general 
ICUs (Toma et al., 2007, n = 6,276, 1 ICU; Toma et al., 2008, n = 2,928, 1 ICU; Ho, 2007, n = 
1,311, 1 ICU; Timsit et al., 2002, n = 1,685, 6 ICUs; Rivera-Fernandez et al., 2007, n = 6,409, 55 
ICUs) and ICU sub-populations in mixed medical-surgical ICU settings (Ferreira et al., 2001, n = 
352; Gosling et al., 2006, n = 431; Moreno et al., 1999, n = 1,449; Zygun et al., 2005, n = 1,436). 
In addition, the model has been applied across different institutions and geographical locations 
(Toma et al., 2007, Vincent & Moreno, 2010; Zygun et al., 2005).  
There were four validation studies identified that compared admission SOFA predictions 
with APACHE II’s performance in medical and surgical ICU patients. Ho et al. (2007) reported 
AUCs for SOFA and APACHE II, 0.791 and 0.858, respectively among a population of 1,311 
patients. Holtfreter et al. (2006) also conducted a retrospective investigation (n = 933) into the 
performance of SOFA (AUC 0.72) and found it discriminating more closely to APACHE II 
(AUC 0.785) but with less accuracy in comparison with the Ho study. Peres-Bota et al. (2002) 
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approach was a prospective, observational study with 949 patients whereby both models showed 
good discrimination but APACHE II (AUC 0.88) performed slightly better than SOFA (AUC 
0.872). On the other hand, Gosling et al. (2006) employed a prospective approach (n = 431) with 
both SOFA (AUC 0.61) and APACHE II (AUC 0.62) showing similar, yet poor discrimination.  
Janssens et al. (2000) conducted a prospective investigation (n = 303) with SOFA (AUC 
0.82) demonstrating superior discrimination in comparison with SAPS II (0.77). Granholm et al. 
(2016) performed a post hoc study resulting in SOFA (0.73) not discriminating as well as SAPS 
II (0.80).  There was one study identified that compared all three models in a large general 
hospital in Pakistan. The study enrollment was small with only 96 eligible medical ICU patients 
(Naqvi et al., 2016).  Descriptions of cancer patient makeup were not elucidated in the 
demographics section. Nevertheless, APACHE II showed somewhat better calibration (p 0.866) 
in comparison to SAPS II (p 0.0811) and SOFA (p 0.32). With an AUC of 0.835, the APACHE 
II model showed superior discrimination power to SAPS II and SOFA which both predicted at 
the same degree of accuracy, AUC = 0.75. Based on these findings, further exploration of SOFA 
application and optimal performance in the oncology ICU sub-population are warranted, to add 
to the current body of research. 
Bedside Context for Prognostic Models 
Because clinical judgment alone is difficult and imprecise, the intent of prognostic model 
use is to objectively inform clinical judgment; not to replace clinical interpretations or serial 
assessments (Hamel et al., 1999; Knaus et al., 1995; Teno et al., 2000). Prognostic models are to 
be regarded as adjunct, objective tools rather than substitutes for clinical judgment and are 
available for use in the shared decision-making process (Feltracco et al., 2011). The application 
of prognostic tools within patient-centered clinical pathways and algorithms may assist with 
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informational needs; thus, ensuring  ICU patients receive timely quality care from ICU nurses as 
well as appropriately prescribed treatments by physicians involved in the care process 
(Costantini, Alquati, & Di Leo, 2014; Constantini et al., 2014; Huffines et al., 2013).  
Again, vPMs aid decisional needs by providing objective information about a patient’s 
clinical status within the first 24 hours of admission to the ICU. These decisional needs are at the 
center of patient/family directives and guide nurse-physician actions at the initiation of care 
(Sepucha, Fowler, & Mulley, 2004; Stacey, Samant, & Bennett, 2008; Stacey, Paquet, & Samant, 
2010; van Mol, 2016). When the use of prognostic models are understood and applied, nurses 
use the information for patient advocacy and physicians rely on it to support treatment 
recommendations (Neville et al., 2015) . The prognostic value is that patients and family as 
surrogate decision-makers have objective information to address decisional needs that cause 
uncertainty, reluctance, and desire for additional information (Barbini et al., 2014; Chien et al., 
2014; Djulbegovic et al., 2016; Becerra-Perez et al., 2016). 
Summary 
In summation, APACHE II, SAPS II, and SOFA have been studied in diverse ICU 
settings (i.e., medical, surgical, neurological, trauma, oncology, cardiac, and surgical units) 
which included sample sizes greater than 1000 patients on a worldwide platform (Cholongitas et 
al., 2006; Godinjak et al., 2016; Hosseini & Ramazani, 2016; Naqvi et al., 2016; Pietraszek-
Grzywaczewska et al., 2016). Most importantly, APACHE II, SAPS II, and SOFA have been 
validated using large, prospective, multi-center, multi-national general ICU population mixes (up 
to 16,000+ patients) that included patients with cancer (Cabré et al., 2005; Livingston et al., 
2000; Moreno et al., 1998; Moreno et al., 1999; Salluh & Soares, 2014; Vincent & Moreno, 
2010; Yu et al., 2014). The findings support claims that each vPM is good at predicting patient 
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outcomes (discrimination) and forecasting mortality (calibration) but with differing degrees of 
predictive accuracy in general ICU populations (Godinjak et al., 2016; Knaus, 2002; Salluh & 
Soares, 2014; Vincent & Moreno, 2010).  
Moreover, the review of literature supported the premise that each model quantifies 
disease severity, determines prognosis, and guides therapeutic interventions. Nevertheless, 
optimal performance comparing APACHE II, SAPS II, and SOFA within the ICU oncology sub-
population remained to be determined. A more in depth appraisal of the literature (i.e., 
systematic review) and synthesis (i.e., meta-analysis) was an opportunity to answer the primary 
research question. The process involved focusing solely on research dedicated to APACHE II, 
SAPS II, and SOFA model applications in the critically ill cancer population. Conducting a 
meta-analysis in this area of research serves as a reference for CCNs and intensivists to explore 
how vPMs can be applied clinically when there is uncertainty, concerns about delivering futile 
care, and decision conflicts. 
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Chapter 3 
Methods 
The overall aim was to determine the predictive accuracy of each vPM by combining 
study results from previous investigations evaluating individual performances of vPMs. Follow 
up statistical analysis included pooling the data to compare overall performances to determine 
greatest predictive accuracy among the three vPMs: APACHE II, SAPS II, and SOFA. No 
human subjects were under investigation and no related ethical considerations were involved in 
the process.  
Research Questions 
The following questions were addressed in this study: 
1. Which prognostic scoring system performs 30-day mortality predictions most 
accurately for critically ill cancer patients admitted to the ICU? 
2. Among the study sample, what physiological variables are reported to be additional 
independent predictors of 30-day mortality for oncology patients in the ICU? 
Design 
A meta-analysis using meta-regression with random-effects model to combine and 
summarize the results of prognostic model validation studies was the study design. Validation 
studies are the main way to assess or validate the performance of a vPM on a new patient 
population. The design of validation studies are to compare predicted and observed mortality 
outcomes for groups of patients (calibration) and to quantify the model’s ability to distinguish 
between patients who do or do not experience the event of interest (discrimination) (Moons et 
al., 2009). These studies tend to report performance outcomes in the form of AUCs. 
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Procedures 
The meta-analysis was performed following the Preferred Reporting Items for Systematic 
Reviews and Meta-analysis (PRISMA) criteria (see Figure 2, pg. 45) (Liberati et al., 2009). An 
extensive search of the literature for studies with similar performance aims (i.e., validating 
predictive accuracy when computed within the first 24 hours of admission) were conducted using 
the following search procedure. Literature searches of CINAHL, PubMed, Web of Science, and 
Cochrane Library databases spanning January 2000 to February 2017 timeframe were completed. 
Each literature search was limited to articles reporting critically ill oncology patients as the study 
population and admitted to the ICU setting. Study participants in articles of interest were 
confined to study populations admitted to the ICU for management associated with cancer-
related diagnoses. 
The search included prospective and retrospective observational cohort studies using the 
following key words and medical subject heading (MeSH) terms:  “Acute Physiology and 
Chronic Health Evaluation II (APACHE II)”  “Simplified Acute Physiology Score (SAPS)”, and 
“Sequential Organ Failure Assessment (SOFA)”  with subheading “oncology”, “cancer”, “ICU” 
and its derivates, “critically ill”, “prognostic model”, “prognostic scoring system”, “severity-of-
illness scores”, “prognosis and outcome”, “prediction” and “mortality”. Search terms combining 
key words with “AND” and “OR” were added for broader searches. Studies were full-text 
English-language, peer-reviewed articles published between January 2000 and February 2017. 
To identify additional studies, reference lists of all eligible articles were examined, crosschecked, 
and included if eligibility requirements were met. 
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Figure 2. PRISMA Flow Diagram 
Reference: Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G. The PRISMA Group (2009). 
Preferred reporting items for systematic reviews and meta-analyses: The PRISMA Statement. 
PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed.1000097 
 
Data Extraction and Collection 
 Data extraction followed the Checklist for Critical Appraisal and Data Extraction for 
Systematic Reviews of prediction Modeling Studies (CHARMS) protocol (Figure 3) (Moon et 
al., 2014).  Data collection involved the use of study-level data instead of individual-level data. 
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Study-level data collected were the performance results of APACHE II, SAPS II, and SOFA 
models reported in peer-reviewed literature. Study-level data analyzed refers to the diagnostic 
performance statistics, AUCs (see “Definition of Terms”) with standard error of the estimates 
(SE), reported in each eligible study.  
Area under the characteristics curve was used for data extraction because it represents the 
degree of concordance between vPM prediction and observed mortality in the study population. 
An AUC of 0.70 to 79 is “fair performance” with AUC 0.80 to 0.89 and 0.90 to 1.0 representing 
“good performance” and “excellent performance”, respectively. Including SEs with its 
corresponding AUC accounted for the standard deviations in each study sampling distribution.  
 
Checklist Item  Example  
 1. Prognostic versus 
diagnostic prediction 
model?  
The aim is to predict future events 
The aim is to detect disease status  
 2. Intended scope of the 
review?  
Models to inform therapeutic decision-making 
Models to inform referral or transfer patient  
 3. Type of prediction 
modelling studies?  
Prediction model development with external validation 
External model validation only  
 4. Target population?  Patients with cancer 
Patients with out-of-hospital cardiac arrest  
 5. Outcome to be 
predicted?  
Specific future event such as “in-hospital” mortality 
Specific disease status such deep vein thrombosis  
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 6. Time span of 
prediction?  
30-day ICU mortality 
31-day to 6 month  mortality  
 7. Intended moment of 
using the model?  
Models to be used upon admission to the ICU from ER  
Models to be used post-operatively in ICU  
Figure 3. CHARMS Key Items Checklist to Guide Systematic Review Process. 
 
Based on Moons, K. G. M., et al. (2014) Critical appraisal and data extraction for systematic 
reviews of prediction modelling studies: The CHARMS Checklist. PLoS Med 11(10): e1001744. 
https://dx.doi.org/10.1371/journal.pmed.1001744 
 
The sample included studies focused on the prognostic performance of APACHE II, 
SAPS II, and SOFA models in the ICU-based adult oncology patient population. The shared aim 
across studies was to validate vPMs ability to discriminate between patients who lived from 
those who died. Model performances were based on discrimination (see “Definition of Terms”) 
calculated within the first 24 hours of admission and endpoint was 30-day ICU mortality. Each 
study included in the meta-analysis reported the AUC as its measure of discrimination. A study 
was excluded if information was insufficient for data extraction. 
To address the secondary research question, articles eligible to answer the primary 
research question were reviewed for additional discussions centered on single physiological 
variables explored for a relationship to ICU mortality. Physiological variables of interest were 
limited to covariates in which univariate analyses were performed to detect a statistically 
significant (p < 0.05) influence on ICU mortality. The intent was to identify and describe 
physiological variables not captured in vPM algorithms but were found to be associated with 30-
day ICU mortality risk. 
The principle investigator independently reviewed and extracted data from eligible 
studies entered into a Microsoft Excel spreadsheet. Demographic data included information such 
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as first author, year of publication, country of origin, sample size, setting, cancer type, study time 
period, and study type. Specific performance-related data extracted included AUCs, standard 
errors [SE], 95% confidence intervals, Hosmer-Lemeshow goodness-of-fit p value, and 
estimation of mortality. To ensure data entry accurateness, data were cross-checked and final 
recheck procedure was conducted prior to statistical analysis.  
Statistical Analysis 
Inferential statistical analyses were performed using MedCalc for Windows version 17.2 
statistical software package (MedCalc Software, Ostend, Belgium). The AUCs with SE were 
extracted from each study to calculate pooled AUCs to answer the primary research question. 
When an SE for an AUC was not provided in a study, the reported number of survivors and non-
survivors were used to estimate it with methods described by Hanley and McNeil (1982). 
Publication bias was analyzed using Egger’s test (Egger et al., 1997) and displayed graphically 
with a funnel plot. 
To Test Heterogeneity 
Statistical analyses were conducted on study-level data extracted from the eligible 
articles. Meta-regression using random-effects model to test heterogeneity was performed on this 
data to determine pooled AUCs results for APACHE II, SAPS, and SOFA. Summarizing pooled 
AUCs provided a more precise estimate of model performance for each vPM (Haidich, 2010). 
When heterogeneity is present, summary measures must be interpreted within the context of 
understanding the nature of variability in and across the studies. Statistical heterogeneity is 
implicit because the performance outcomes in the studies are untenable. 
There was also the assumption of no single true effect (i.e., the outcome in each study is 
the same) due to variations in the characteristics of study populations and methodologies applied 
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from study to study. The premise is that clinical and methodological diversity increases the 
chances of statistical heterogeneity (Preuss & Ziegler, 2014). Therefore, random-effects 
modeling was applied because it assumes 1) variability in study designs, 2) that differences in 
underlying study populations exist, and 3) outcomes will vary across studies.  
First, data was grouped according to prognostic model and then random-effects modeling 
was added to statistical analysis to account for between-study variance (τ²). The random 
variation within the studies plus the variation between the different studies was addressed using 
this method. In random-effects modeling, the study variance is inversely weighted with the   
heterogeneity parameter (Cochran’s Q test and Higgins I squared statistic) (Haidich, 2010; 
Preuss & Ziegler, 2014). The summary weighted mean effect (i.e., weighted performance mean 
for APACHE II, SAPS II, and SOFA) was then generated so that a pooled analysis would 
determine greatest predictive accuracy among the three vPMs.  
The heterogeneity of the pooled AUCs was measured using Cochran’s Q test and Higgins 
I squared (I²) statistic. Statistical significance for the Q test was defined as p < 0.1 (because of 
low power) and I² > 50 percentage. Statistical heterogeneity was expected because of the 
methodological differences between the vPMs involved in making mortality predictions. For 
example, the models differ in number and predictor variables such as the SAPS II uses blood 
urea nitrogen versus SOFA uses serum creatinine to represent renal function. However, the 
vPMs measure the same three physiological variables which are Glascow Coma Score for 
neurological assessment and  partial pressure of O2 in arterial blood [paO₂] with fraction of 
inspired oxygen [FiO²]) to determine tissue oxygenation.  
In summation, the random-effects model in this study produced a distribution of true 
effects (a series of AUCs) with no missing data for all studies in each vPM group. The random-
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effects model combined true effects of these studies to estimate the weighted mean performance 
because of τ² in each group distribution. This process resulted in summary AUCs for APACHE 
II, SAPS II, and SOFA with single-value pooled estimates of the weighted mean performance 
(i.e., mean distribution of AUCs) for each model distribution. After generating summary AUCs, 
the pooled effects of APACHE II, SAPS II, and SOFA performances were compared to 
determine the vPM with greatest predictive accuracy. 
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Chapter 4 
Results 
The selection process using PRISMA criteria is shown below (Figure 4). Initially, 227 
published articles were identified using the first search strategy. After screening titles and 
abstracts, 57 potential studies were reviewed in full-text format. After reading these studies, 22 
eligible validation studies met the inclusion criteria. 
Description of Sample 
A minimum of 10 studies for each vPM was sought to obtain meaningful interpretations 
to support an evidence-based conclusion (Borenstein et al., 2009).  The search yielded 22 
validation studies reporting performance outcomes for the three vPMs in the critically ill 
oncology ICU sub-population. Among the 22 validation studies, there were 16 articles, 15 
articles, and 8 articles reporting AUCs for APACHE II, SAPS II, and SOFA models, 
respectively. Some studies included more than one group of study subjects who underwent 
mortality risk estimation by more than one vPM. As a result, the search yielded a total of 21 
reported AUCs for APACHE II, 18 AUCs for SAPS II, and 10 AUCs for SOFA (see Appendix 
E). 
 Key characteristics of the identified studies analyzed are shown in Appendix F. Together, 
the 22 validation studies comprised 13 countries spanning four continents (Asia, Europe, North 
America, and South America) and the Middle East. Study periods spanned the 1990s to 2011 in 
228 hospitals with two independent studies conducted at one hospital in Mexico during the same 
time-period. There were four categories of hospitals identified – university, university-affiliated 
oncology specialty, tertiary oncology specialty, and tertiary community. All studies (12 
retrospective cohorts, 10 prospective cohorts and one combined retrospective and prospective 
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cohort) were set in adult medical and surgical ICUs. Eleven ICUs were dedicated to treating 
oncology-only patients.  
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A majority of the studies were validation studies testing the performance of the vPMs. 
There were three out of the 22 validation studies that included testing a new model (model 
development) while comparing the performance with established vPMs. Sixteen studies reported 
findings for APACHE II (73%), 15 studies included SAPS II (68% ), and 8 studies (36%) 
measured SOFA performance. A combined 14,644 patients with 25 cohorts (three studies had 
two separate groups) comprised this study. The sample sizes ranged from 50 to 7,689 adult 
oncology ICU patients. The oncology patient mix was 10 solid/hematological cohorts, three 
hematological malignancies cohorts, three colorectal cancer cohorts, two solid tumor cohorts, 
and one cohort each for: Acute Myeloid Leukemia, Acute Myeloid Leukemia with Non-
Hodgkins lymphoma, gastric cancers, and gynecological cancers.  
Some validation studies reported AUCs for two or more models. Other studies reported 
AUCs for more than one sample population. This resulted in the performance of a vPM 
sometimes reported more than once in an article to represent predictions performed on different 
patient groups in the study (see Appendix E). For example, Cardenas-Turanzas et al (2012) 
conducted a validation study evaluating the performance of SOFA in two cohorts: n = 540 
medical ICU oncology patients and n = 783 surgical ICU oncology patients. The SOFA 
performance was an AUC of 0.79 (0.024 SE) in the medical ICU group and 0.79 (0.063 SE) in 
the surgical ICU group.  
Models and Predictions in the Sample  
In totality, there were 32,303 combined predictions performed among the three vPMs in 
this meta-analysis. In the APACHE II cohort group, 16,764 mortality predictions were tested for 
predictive accuracy across 22 validation studies. Among the SAPS II and SOFA cohort groups, 
the models made 12, 960 (18 articles) and 2,579 (10 articles) total predictions, respectively. The 
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combined findings from all predictions led to sorting outcomes into three groups of pooled 
estimates to best summarize the overall performances of APACHE II, SAPS II, and SOFA 
models. 
Models Performance Statistics 
For this study, the focus was on the discriminating power of vPMs. As stated earlier, 
discrimination refers to a model’s ability to make predictions by differentiating between 30-day 
ICU survivors and 30-day ICU non-survivors with accuracy. It is reported via the AUC, which is 
expressed in the form of a correlation coefficent ranging from 0 to 1. Discrimination, measured 
by AUCs, for APACHE II (n = 16,764 predictions) ranged from 0.60 to 0.94 with 0.80 mean 
(95% CI 0.761 to 0.848, 0.095 SD, SEM 0.021, variance 0.008). Discrimination for SAPS II (n = 
12, 960 predictions) ranged from 0.67 to 0.92 with 0.792 mean (95% CI 0.760 to 0.824, 0.063 
SD, SEM 0.015, variance 0.004). Discrimination for SOFA (n = 2,579 predictions) ranged from 
0.68 to 0.91 with 0.785 mean (95% CI 0.735 to 0.834, 0.069 SD, SEM 0.021, variance 0.004).  
The data comes from different studies and diverse populations resulting in the need to 
perform a goodness-of-fit test to account for potential discrepancies between predicted and 
observed outcomes. The D’Agostino-Pearson to test for normal distribution of the true effects 
(AUCs) was p = 0.467 (p > 0.05, accept normality) for the APACHE II model overall 
performance in validation studies (Sheskin, 2011). The D’Agostino-Pearson test for SAPS II and 
SOFA models overall performances were p = 0.983 and SOFA was p = 0.837, respectively. 
Results of the D’Agostino-Pearson test indicate all models had normal distributions. 
Independent samples t-test for assumption of homogeneity of variances was tested 
between APACHE II and SAPS II model groups and APACHE II and SOFA model groups. 
Homogeneity of variances was satisfied via F test for equal variances (p = 0.364). Considering 
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there were unequal numbers in each cohort, the Welch test was performed for unequal variances, 
F (23.4) = - 0.565, two-tailed p = 0.577. These steps were repeated between SAPS II and SOFA 
model groups. Homogeneity of variances was satisfied via F test for equal variances (p = 0.738). 
Welch test for unequal variances showed F (17.5) = 0.271, two-tailed p = 0.789.  The results 
were non-significant confirming no difference between the means of the three model groups.  
Because the vPMs use different, yet similar combinations of physiological variables to 
predict mortality, there was an assumption of independence among the performances of the three 
models. Pearson product-moment correlation coefficient was computed to assess the relationship 
between APACHE II and SAPS II. There was no correlation between the two models (r = -0.016, 
p = 0.950). This step was followed by examining the relationship between APACHE II and 
SOFA. This also showed no correlation between the two models (r = -0.185, p = 0.608).  The 
SAPS II and SOFA showed greater correlation (r = 0.290, p = 0.608) but lacked statistical 
significance. This implies the vPMs are independently, discrete from one another. 
Heterogeneity Testing 
As stated earlier, meta-regression to test heterogeneity using random-effects model was 
performed on study-level data to determine the summary AUCs for APACHE II, SAPS II, and 
SOFA. The random-effects model (Zhou et al., 2002 method) was used to analyze the pooled 
AUCs because heterogeneity was significant for all 3 vPMs (see Table 5) and the study sample 
observed outcomes were expected to be varied. Statistical significance for the Q test was found 
(Q = p < 0.001) and Higgins I² was > 50 percent for all three vPMs.  
Results of the Q test and Higgins I² confirm substantial heterogeneity for all cohorts. 
Together, the Cochran Q test of homogeneity (p = < 0.0001) with Higgins I² (> 50%), which 
quantifies the degree of heterogeneity, determined the studies were not homogeneous. The 
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results showed true heterogeneity between studies for APACHE II (I² = 94.56%), SAPS II (I² = 
94.66%), and SOFA (I² = 80.21%). These finding were expected because the studies were not 
from a common population. 
 
A meta-regression requires weight be assigned to each pooled study. Cochran’s Q is the  
weighted sum of squares and reflects the total dispersion of studies around the grand mean. Each 
Q statistic was evaluated with respect to its degrees of freedom and the weighted pooled studies 
are graphed in forest plots (Figures 5, 6 and 7). To the left of each forest are the studies reporting 
the AUC for the respective cohort group. The studies are listed alphabetically and repeated when 
2 or more AUCs are reported in its outcomes. Each study is represented by a filled square to 
denote its AUC and the horizontal line signifies the corresponding 95% confidence interval. The 
diamond at the bottom of each graph is the pooled estimated mean performance and width 
reflects the precision of that estimate based on random-effects modeling. 
Table 5.  
Test of Heterogeneity 
*Q is the weighted sum of squares on a standardized scale. It is reported with a p value with 
low P-values indicating presence of heterogeneity. I
2
 is the percentage of observed total 
variation across studies that is due to real heterogeneity rather than chance. It is calculated 
as I
2
 = 100% x (Q - df)/Q. A value of 0% indicates no observed heterogeneity and larger 
values show increasing heterogeneity.  
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Figure 5. APACHE II Cohort: Pooled Weighted Studies 
 
Liborio et al. (2011) prospective study (n = 288, hematological/solid cancer) with oncology only 
MSICU patient mix performed best in the APACHE II cohort with AUC 0.940. Sculier et al. 
(2000) had the worst performing study (n = 261, hematological/solid cancer) with oncology only 
MSICU patient mix reporting an AUC of 0.60.The overall pooled magnitude of weighted effect 
in this cohort was 0.804 (95% CI 0.763-0.845). 
Estimated  performance 
mean 
AUC = .804 [95% CI 0.763 – 
0.845] 
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Figure 6. SAPS II Cohort: Pooled Weighted Studies 
 
Soares et al. (2004) prospective study (n = 1,257 patients with hematological/solid cancers) in a 
MSICU performed best in the SAPS II cohort with AUC 0.916. Sculier et al. (2000) prospective 
study had the worst performing outcome (n = 261, hematological/solid cancer) for SAPS II with 
oncology only MSICU patient mix reporting an AUC of 0.67.The overall pooled magnitude of 
weighted effect in this cohort was 0.797 (95% CI 0.763-0.845). 
 
 
 
 
 
 
 
 
 
Estimated performance 
mean 
AUC = .797 [95% CI 0.766 
– 0.828] 
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Figure 7. SOFA Cohort: Pooled Weighted Studies 
 
Liborio et al. (2011), prospective study (n = 288 patients with hematological/solid cancers) in a 
MSICU performed best in the SOFA cohort with AUC 0.910 while the overall pooled magnitude 
of effect in this cohort is 0.794 (95% CI 0.749 – 0.839). Greenberg et al. (2016) had the worst 
performing study (n = 245, hematology cancers) with an AUC of 0.65 that was conducted 
retrospectively in a MICU. This model was being compared to a development model in the 
primary study. 
 
 
 
 
Estimated  performance 
mean 
AUC = .794 [95% CI 0.749 – 
0.839] 
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 The pooled or summary AUCs for APACHE II, SAPS, and SOFA were 0.804, 0.797, and 0.794, respectively (see Table 6). 
The APACHE II demonstrated good discrimination while SAPS II and SOFA showed fair discrimination. The fixed-effect model was 
invalid because heterogeneity was significant for all three vPMs and confirmed why random-effects modeling was selected (see Table 
5). The random-effects AUCs were then compared (APACHE II with SAPS II, p = 0.7897, APACHE II with SOFA p = 0.7471, SAPS 
II with SOFA p = 0.9147) for all models. The findings led to the statistical conclusion that the performances of AUCs for the three 
cohorts are not significantly different; therefore, the weighted performance means are similar.  
Table. 6. 
Summary AUC with Random-Effects Model 
The pooled Area under the ROC curve with 95% CI is given both for the Fixed effects model and the Random 
effects model.  
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Accounting for Bias 
Publication bias is a threat to the validity of clinical research, which can distort the 
totality of the available evidence on a research question. This can lead to misleading inferences 
in systematic reviews and meta-analyses (Haidich, 2010). The Egger’s test was performed to 
detect publication biases (e.g., only publishing studies with favorable outcomes), which were 
depicted graphically using funnel plots. There are more than 10 articles with statistically 
significant findings in each study included in this meta-regression, making it appropriate for 
testing (Egger et al., 1997; Sterne & Egger, 2001).  
Funnel plots are displayed below for each cohort of vPM studies (Figures 8, 9, and 10). 
The unfilled circles are plotted according to the reported AUCs (x-axis) and corresponding SEs 
(y-axis). Two diagonal lines represent (pseudo) 95% confidence limits (effect ± 1.96 SE) around 
the summary effect for each standard error on the vertical axis. If publication bias is present, the 
funnel plot will be asymmetrical. 
Both APACHE II (Figure 8) and SAPS II (Figure 9) cohorts showed symmetry. The 
SOFA cohort (Figure 10) was expected to be vulnerable to bias due to the smaller number of 
studies (low statistical power) included in this model cohort. It is asymmetrical because the 
majority of the AUCs are not evenly dispersed in the funnel; rather, they collected to the left of 
0.8 median. Low statistical power in the presence of heterogeneity can lead to false claims of 
publication bias (Loannidis & Trikalinos, 2007). The SOFA cohort was asymmetrical implying 
publication bias. However, smaller number of studies (n = < 10) tend to show larger effects that 
mimic bias and reduced heterogeneity may be exaggerated by the small sample size.  
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Figure 8. APACHE II Funnel Plot Asymmetry Test 
 
Symmetrical plot 
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Figure 9. SAPS II Funnel Plot Asymmetry Test 
 
Symmetrical plot 
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Figure 10. SOFA Funnel Plot Asymmetry Test 
 
 
Independent Predictors of Mortality 
The secondary aim of the study was to identify independent predictors of mortality 
measured and reported in the 22 eligible validation studies. Physiological variables of interest 
were limited to physiological covariates in which univariate analyses were performed to detect a 
statistically significant (p < 0.05) influence on ICU mortality. The intent was to identify and 
describe physiological variables not captured in vPM algorithms and were associated with 30-
day ICU mortality risk. 
Physiological variables identified as independent predictors, but already measured in a 
model, were not included in data extraction. As a result, the inquiry yielded no results. For 
 
Asymmetrical plot 
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example, Benoit et al. (2003) identified requiring intubation within the first 24 hours of 
admission, serum creatinine > 1.2, and blood urea nitrogen > 0.75, leucopenia, and the use of 
vasopressors as prognostic indicators of 30-day ICU mortality. These variables are already 
measured in the vPMs; therefore, offer no meaningful insights for this type research question. 
The most frequently occurring independent prognostic indicator of mortality risk was the use of 
vasopressors, which is measured in the SOFA model.  
In the Soares et al. (2004) study (n =1,257), APACHE II (AUC 0.89) and SAPS II (0.92) 
showed good to excellent discrimination without independent prognostic variables explored in 
the analysis. The Liborio et al. (2011) study (n = 288) also showed good (SAPS II, AUC 0.869) 
and excellent (APACHE II, AUC 0.940; SOFA, AUC 0.910) discrimination. In this study, the 
authors identified 13 physiological variables that increased risk for hospital mortality but the 
models also address these predictors. After surveying the articles, there was insufficient data to 
analyze, summarize, or describe independent predictors associated with 30-day ICU mortality 
not captured in the vPMs.  
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Chapter 5  
Summary  
The approach chosen to determine the vPM most suitable for the critically ill cancer 
population was a meta-analysis using meta-regression with random-effects modeling technique. 
Study-level data were extracted from prospective and retrospective cohort-type validation studies 
aimed at the predictive accuracy of APACHE II, SAPS II, and SOFA models. After applying 
PRISMA criteria to the literature search, 22 articles met eligibility criteria. The CHARMS 
protocol guided data extraction. Together, PRISMA criteria and CHARMS protocol was a 
structured approach to organizing the steps to answering the research questions and reporting the 
outcomes. 
Systematically reviewing the literature provided a sufficient amount of data to generate 
diagnostic performance statistics. The processed yielded 32,303 combined predictions performed 
among the three vPMs. The APACHE II, SAPS II, and SOFA cohort groups performed a total of 
16,764, 12,960, and 2,579 mortality predictions respectively. Predictive accuracy for APACHE 
II ranged from 0.60 to 0.94 (0.800), SAPS II 0.67 to 0.92 (0.792), and SOFA 0.68 to 0.91 (0.794) 
across the 22 validation studies.  
Random-effects accounted for between-study variance and heterogeneity, resulting in a 
weighted mean for individual studies and pooled mean effects. Study weights led to APACHE II 
cohort performance mean increasing slightly to 0.804 from the 0.800 after accounting for 
heterogeneity. The SAPS II cohort performance mean increased to 0.797 when compared to the 
0.792 before random-effects modeling.  The SOFA cohort improved most with an initial 0.785 
that changed to 0.794 performance mean effect. The conclusion is APACHE II demonstrated 
good discrimination while SAPS II and SOFA showed fair discrimination.  
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The overall performance means for APACHE II, SAPS, and SOFA were 0.804, 0.797, 
and 0.794, respectively. Based on the findings, the APACHE II demonstrated greatest predictive 
accuracy when compared to SAPS II and SOFA models. Although APACHE II performed best, 
clinical significance is not established based on these findings. Measures of correlation among 
vPMs demonstrated no relationships between the models. Adjunct to vPM research, no 
independent predictors of to 30-ICU mortality were identified in this study.    
Discussion 
Diversity among researchers tends to lead toward different approaches to investigating 
important questions. In this study, examining previous works centered on questions about the 
performances of vPMs in the ICU wasdeemed important to delivering quality bedside care. The 
varying approaches to uncovering the answer to vPM performances created an opportunity to 
integrate the findings from multiple independent studies to inform evidence-based practice. 
Similarities in methodologies and aims centered on the vPM performances in the critically ill 
oncology population resulted in independent studies being aggregated using statistical 
procedures to quantify significance to bedside care.  
Sample 
Following PRISMA guidelines, this study was a systematic attempt at quantifying the 
results of independent research to gain evidence-based knowledge that will further guide clinical 
practice. A limitation of this approach is study-level data. In contrast to data at the subject-level, 
study level data is restricted to information available for extracting from independent reporting 
of findings. Issues such as individual study bias, design flaws, and improper data collection 
techniques cannot be managed using the methodological approach in this study. Nevertheless, 
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the random-effects models accounted for heterogeneity associated with differences in 
characteristics of studies and study populations. 
The CHARMS protocol added scientific rigor because it pre-specified the objectives and 
methods of data extraction. The study sample was limited to validation studies that were testing 
vPMs performances in new populations (i.e., oncology patients) to determine if clinical validity 
was maintained in specific patient groups. A strong point of this approach is the ability to isolate 
the performances in a group for analysis. The limitation of this approach was the lack of model 
performance comparisons with performances in general ICU populations. Whether or not the 
models perform better in the general population remains unknown. 
Following the CHARMS protocol restricted post hoc decisions during the review 
process; thus limiting bias such as selective outcome reporting. Publication bias is a concern for 
publishing only studies that demonstrate favorable outcomes. The Egger’s test showed no 
publication bias associated with the APACHE II and SAPS II cohorts. The AUC performances in 
each group varied: 0.60 to 0.94 (APACHE II), 0.67 to 0.92 (SAPS II), and 0.68 to 0.91 (SOFA). 
The APACHE II cohort demonstrated the widest range gap (0.34) and SOFA had the narrowest 
range gap (0.23). The small sample of studies identified for the SOFA model can be attributed 
low statistical power and reduced heterogeneity.  
Primary Study Aim 
 A validated prognostic model performance is related directly to the ratio between 
accurate predictions and observed outcomes when establishing legitimacy for bedside 
application. In this study, APACHE II performed with greatest accuracy but had significantly 
more predictions in comparison with the other models. It is the gold standard among vPMs, 
which can be attributed to the availability of more studies and greater reporting of prediction 
69 
 
events. The least performing vPM, SOFA, had significantly fewer predictions because of fewer 
published studies available for statistical analysis. The SAPS II model’s overall performance was 
closer to APACHE II, which coincided with a comparable number of prediction events.  
The strength of using meta-regression to summarize the findings of multiple studies is its 
scientific approach. It objectively reduces conflict and ambiguity associated with examining the 
evidence based solely on case-by-case analysis. A key limitation is the grouping of performance 
assessed based on study-level data. In this study, the data is based on model overall performance 
(i.e., mean) as reported in individual studies rather than scrutiny of performance at the individual 
level. Predictive accuracy cannot be stratified using study-level data.  
Individual level data is more appropriate for observing performance differences 
representative of physiological extremes and gray areas. For example, a vPM performance 
among terminally ill patient populations is probably greater than 0.9 (i.e., excellent 
discrimination). Likewise, vPM performance for patients admitted for low acuity needs such as 
observation status is also favorable towards high predictive accuracy. Evidence supporting the 
validity of vPMs are important to the bedside nurse and physician. However, research of 
prognostic models outcomes among cancer patients with clinically ambiguous situations may be 
more meaningful. As a result, predictions that are objective for oncology patients who fall in the 
uncertainty category still need to be addressed in future research. 
Secondary Study Aim  
The secondary aim of the study was the identification of independent predictors of ICU 
mortality not included in APACHE II, SAPS II, and SOFA models. The impetus for this 
exploration was to gain new insights into routinely measured physiological variables that may 
improve the predictive performance of any widely accepted vPM. Identifying independent 
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predictors of mortality are important to clinical nursing because early warning signs are a part of 
critical thinking and anticipatory care in nursing practice. After surveying the articles, there was 
insufficient data to analyze, summarize, or describe independent predictors associated with 30-
day ICU mortality not captured in the models.  
Ongoing investigation is required to determine independent predictors of mortality, not 
measured in the models. Restricting the search of independent predictors to reporting along with 
model performances was a limitation of this study. Conducting a meta-analysis of independent 
predictors may better address the secondary aim. This is more salient when examined in the 
context of the primary findings. That is to say, the main effects of vPMs in this study ranged 
from fair to good discrimination (0.0794 – 0.804). Identifying covariates that better capture the 
unique physiological challenges associated with cancer and its related treatment must be 
investigated to determine if the overall performance of model predictions can be improved to > 
0.90 in this population. 
Conclusion 
As the gold standard among vPMs, APACHE II performed with greatest predictive 
accuracy and achieved good discrimination (> 0.80). Its combination of physiological variables, 
prediction algorithm and objectivity remained valid after scrutiny in this study. Heterogeneity 
was established across studies with no publication bias observed. Because the outcome is based 
on study-level data, ongoing research is need to explore the clinical significance and practical 
application of APACHE II in the critically ill oncology ICU sub-population. Pursuing clinical 
significance is an opportunity to examine feasibility, impact of use on staff attitudes, and 
application to decision-making at the bedside.  
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The overall performance was 0.804 for APACHE II. Nevertheless, a model that predicts 
at 0.9 or better (excellent discrimination) would be ideal. Because the model has not reached its 
full potential, the identification of additional physiological variables associated with ICU 
mortality using a different approach is warranted. In effect, identifying physiological variables 
most predictive of outcomes in the oncology patient will lead to the need to update current 
models. This includes adding variables representative of homeostasis, modifying algorithms, and 
ensuring that model changes improve performance and maintain objectivity. 
Although SAPS II and SOFA did not perform as well, improving performance remains an 
important contribution to critical care management. A contributing factor to SOFA performance 
may be due to it being under-investigated in the cancer population. Cancer is one of the leading 
causes of death worldwide, but the overall number of articles retrieved was small relative to 
disease impact. Having a small number of studies to review was a limitation of conducting meta-
analysis to answer both research questions. Limited information to support evidence-based 
practice supports continued nurse-led investigations centered on prognosis-related research.  
Nursing Implications 
The utility of prognostic models relies on capturing and documenting the physiological 
variables observed by CCNs during hemodynamic monitoring. These physiological variables 
function as prognostic factors by which the intensivists use the information to formulate a 
realistic clinical picture in collaboration with the bedside nurse. Together, the CCNs and 
intensivists use their expertise and practice scopes to demonstrate their collective investment in 
the well-being of the patient and assurance of delivering evidence-based, quality care. Therefore, 
future research should be centered on how prognostic information is shared at the bedside.  
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Prognosis research is central to addressing these types of issues in the clinical setting. 
Nurse-led research should focus on the contextual meaning of prognosis to the nurse and patient. 
Understanding its meaning will help CCNs better function as advocates during the decision-
making process. Nursing investigation exploring vPM use as decision support aids have the 
potential to be far reaching. Particularly, nursing investigation should focus on the ICU setting 
because admission to the ICU is associated with anxiety and fears experienced among patients 
and family members; while nurses and physicians have concerns about delivering futile care.  
Shared decision-making is a process and model use has implications for helping to reduce 
uncertainty experienced by patients, nurses, and physicians during a most critical time. Because 
prognosis involves two-way conversations, careful consideration for how vPMs are introduced 
into communication exchanges is important to advance nursing science. Explanations of 
prognoses should be undergirded by rich information delivered in a systematic, impartial, yet 
empathetic fashion but gaps in the literature exist about the role of nursing. This gap creates an 
opportunity for nurse-led investigation related to prognosis and nursing advocacy, education, and 
policy.  
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Appendix A. Combination ICU Mortality Model 
 Use the worst value (US units) for each physiological variable within the past 24 hours. 
VITALS 
HR BP RR Temp GCS 
 
bpm  
/  
mmHg 
 
bpm 
 
C or F  
 
 
ARTERIAL BLOOD GAS 
pH pCO2 pO2 FiO2 
 
 
mmHg
 
 
mmHg
 
% 
Mechanical ventilation or CPAP  
Yes No  
 
CHEM-7 
Na K CO2 BUN SCr 
mEq/L mEq/L mEq/L mg/dL  
mg/dL
 
Acute renal failure  Yes No  
Combination of APACHE II, SAPS II, and SOFA models to predict hospital mortality. 
Publically available at http://clincalc.com/IcuMortality/Default.aspx 
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Appendix A. Combination ICU Mortality Model (continued) 
CBC 
WBC Hct Plt 
x 109/L % x103/mm3 
MISC METRICS 
Urine output mL 
per hour
 
Bilirubin mg/dL  
Vasopressors No Yes  
CHRONIC HEALTH 
Age years 
Chronic diseases 
Metastatic cancer  
Hematologic malignancy  
AIDS  
Type of admission  Scheduled (elective) surgical  
Does this patient have severe organ system 
insufficiency or is immunocompromised? See 
definitions  
No Yes  
Reset Calculate
 
Combination of APACHE II, SAPS II, and SOFA models to predict hospital mortality. 
Publically available at http://clincalc.com/IcuMortality/Default.aspx 
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Appendix B. Acute Physiology and Chronic Health Evaluation II 
Use the worst value (US units) for each physiological variable within the past 24 hours. 
Age years 
Glasgow coma score  
Vitals  
Temp C or F  
MAP mmHg 
Heart rate bpm  
Resp rate bpm  
Oxygenation  
FiO2 %  
PaO2 mmHg  
Arterial pH  
Chemistry  
Sodium mEq/L 
Potassium mEq/L 
Creatinine mg/dL  
Acute renal failure No Yes  
Hematology  
Hematocrit % 
WBC x 109/L 
Severe organ system insufficiency or is 
immunocompromised  No Yes  
Reset Calculate
 
APACHE II model to predict 30-day ICU mortality. Publically available at 
http://clincalc.com/IcuMortality/APACHEII.aspx 
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Appendix C. Simplified Acute Physiology Score II 
Age years 
Vitals  
Heart rate bpm  
Systolic BP mmHg 
Temp C or F  
Glasgow coma score  
Oxygenation  
Mechanical ventilation or CPAP Yes No  
 
PaO2 mmHg  
FiO2 % 
Renal  
Urine output mL 
per hour
 
BUN mg/dL  
Chemistry  
Sodium mEq/L 
Potassium mEq/L 
Bicarbonate mEq/L 
Bilirubin mg/dL  
Other  
WBC x 109/L 
Chronic diseases 
Metastatic cancer  
Hematologic malignancy  
AIDS  
Type of admission Scheduled surgical  
SAPS II model to predict 30-day ICU mortality. Publically available at 
http://clincalc.com/IcuMortality/APACHEII.aspx 
122 
 
Appendix C. Simplified Acute Physiology Score II (continued)  
Use the worst value (US units) for each physiological variable within the past 24 hours. 
SAPS II model to predict 30-day ICU mortality. Publically available at 
http://clincalc.com/IcuMortality/APACHEII.aspx 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reset Calculate
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Appendix D. Sequential Organ Failure Assessment 
Use the worst value (US units) for each physiological variable within the past 24 hours. 
Respiration  
FiO2 % 
PaO2 mmHg 
Mechanical ventilation  No Yes  
Coagulation  
Platelets x103/mm3 
Liver  
Bilirubin mg/dL  
Neurological  
Glasgow coma score  
Cardiovascular  
MAP mmHg 
Vasopressors No Yes  
Renal  
Creatinine mg/dL  
Urine output Greater than 500 mL/day  
Reset Calculate
 
SOFA model to predict 30-day ICU mortality. Publically available at 
http://clincalc.com/IcuMortality/SOFA.aspx 
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Appendix E. Overall Predictive Performance of Prognostic Models in the Literature 
Study Prognostic 
Model  
 (validation 
groups only) 
AUC Standard Error 
(SE) 
95% Confidence 
Interval 
Hosmer-
Lemeshow 
goodness-of-fit 
p value 
1.Benoit,  
et al (2003) 
APACHE II 
 0.71 0.043 NP* 0.39 
SAPS II 
 0.77 0.043 NP 0.6 
2. Berghmans,  
et al (2004) 
SAPS II 
 0.72 0.045 NP < 0.001 
APACHE II 
 0.65 0.047 NP 0.002 
3. Can, 
 et al (2008) 
APACHE II 
 0.79 0.083 0.62 – 0.95 NP 
SAPS II  
 0.85 0.056 0.75 – 0.96 NP 
4. Cardenas-Turanzas,  
et al (2012) 
SOFA ¹ 
 0.79 0.024 0.74 – 0.83 0.87 
SOFA ² 
 0.79 0.063 0.63 – 0.94 0.01 
5. Cornet, 
 et al (2005) 
SOFA 
 0.77 0.061 0.65 – 0.90 NP 
SAPS II 
 0.70 0.068 0.56 – 0.84 NP 
6. Ertan,  
et al (2008) 
SAPS II 
 0.83 0.064 NP 0.98 
APACHE II 
 0.78 0.070 NP 0.49 
7. Fang,  
et al (2014) 
APACHE II ³  
 0.87 0.021 0.83 – 0.91 0.13 
APACHE II ⁴ 
 0.83 0.043 0.75 – 0.91 0.13 
¹Validation cohort, n = 540 medical patient group; ² Validation cohort, n = 783 surgical patient group; ³ Validation cohort, n = 
851 patients; ⁴ Validation cohort, n = 665 patients; *NP – Not provided 
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Study (continued…) Prognostic 
Model  
 (validation 
groups only) 
AUC Standard Error 
(SE) 
95% Confidence 
Interval 
Hosmer-
Lemeshow 
goodness-of-fit 
p value 
8. Greenberg, 
 et al (2016) 
SOFA ⁵ 
 0.68 0.038 0.61 – 0.76 0.25 
APACHE II ⁶  
 0.65 0.039 0.58 – 0.73 0.31 
9. Hampshire,  
et al (2009) 
 
 
 
APACHE II 
 0.74 0.006 0.73 – 0.76 < 0.001 
SAPS II 
0.74 0.006 0.73 – 0.75 < 0.001 
10. Kopterides, 
 et al (2011) 
APACHE II 
 0.90 0.030 0.84 – 0.95 0.17 
SAPS II 
 0.83 0.040 0.75 – 0.89 0.22 
SOFA 
 0.87 0.030 0.80 – 0.93 0.14 
11. Lamia, 
 et al (2006) 
SAPS II ⁷ 0.78 0.048 0.69 – 0.88 0.92 
SAPS II ⁸ 0.79 0.047 0.69 – 0.89 0.92 
SOFA⁷ 0.78 0.048 0.69 – 0.88 0.32 
SOFA⁸ 0.79 0.047 0.68 – 0.89 0.32 
12. Liborio,  
et al (2011) 
APACHE II 
 0.94 0.016 0.92 – 0.97 0.24 
SAPS II 
 0.87 0.023 0.83 – 0.91 0.24 
SOFA  
 0.91 0.020 0.88 – 0.94 0.24 
13. Merz, 
 et al (2008) 
SAPS II 
 0.80 0.060 0.70 – 0.90 Og** 
SOFA 0.69 0.067 0.57 – 0.80 Og 
⁵ ⁶ Validation cohort, n = 196 patients; ⁷ Validation cohort, n = 92 patients; ⁸ Validation cohort, n = 81 excluding allogenic 
Hematopoietic Stem Cell Transplantation patients. 
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Study (continued…) Prognostic 
Model  
 (validation 
groups only) 
AUC Standard Error 
(SE) 
95% Confidence 
Interval 
Hosmer-
Lemeshow 
goodness-of-fit 
p value 
14. Namendys-Silva, 
 et al (2010) 
APACHE II 
0.92 0.031 0.88 – 0.96 0.25 
15. Namendys-Silva, 
 et al (2012) 
APACHE II 
 0.83 0.088 0.73 – 0.95 0.62 
APACHE II 
 0.87 0.031 0.88 – 0.96 0.25 
16. Pohlen,  
et al (2016) 
SAPS II 
 
 
0.73 0.034 0.66 – 0.80 NP 
SOFA 
 0.78 0.032 0.71 – 0.86 NP 
17. Schellongowski,  
et al (2004) 
APACHE II ⁹ 
 0.78 0.036 0.71 – 0.83 0.06 
SAPS II ⁹ 
 0.83 0.027 0.77 – 0.88 0.07 
18. Sculier,  
et at (2000) 
APACHE II 
 0.60 0.038 NP < 0.001 
SAPS II  
 0.67 0.037 NP < 0.001 
19. Soares,  
et al (2004) 
APACHE II ¹⁰  
0.89 0.010 0.87 – 0.91 < 0.001 
APACHE II ¹¹  
0.75 0.021 0.71 – 0.79 < 0.001 
SAPS II ¹⁰  
0.92 0.009 0.90 – 0.93 < 0.001 
SAPS II ¹¹  
0.82 0.018 0.78 – 0.85 < 0.001 
20. Soares,  
et al (2010) 
SAPS II ¹² 
 0.84 0.021 0.81 – 0.87 0.007 
SAPS II ¹³ 
 0.77 0.026 0.72 – 0.82 0.94 
⁹ Validation cohort, n = 242 medical cancer patients; ¹⁰ Validation cohort, n = 1257 including scheduled surgery patients; ¹¹ 
Validation cohort, n = 542 medical and emergency surgical patients only. 
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Study (continued…) Prognostic 
Model  
 (validation 
groups only) 
AUC Standard Error 
(SE) 
95% Confidence 
Interval 
Hosmer-
Lemeshow 
goodness-of-fit 
p value 
21. Xing,  
et al (2015) 
APACHE II ¹⁴ 
 0.86 0.036 0.804 – 0.923 0.900 
APACHE II ¹⁵ 
 0.87 0.069 0.774 – 0.958 0.594 
APACHE II ¹⁶ 
 0.83 0.045 0.757 – 0.911 0.594 
22. Yan, 
 et al (2012) 
APACHE II 
 0.78 0.029 0.72 – 0.83 NP 
 
¹Validation cohort, n = 540 medical patient group; ² Validation cohort, n = 783 surgical patient group; ³ Validation cohort, n = 851 patients; ⁴ 
Validation cohort, n = 665 patients; ⁵ˏ⁶ Validation cohort, n = 196 patients; ⁷ Validation cohort, n = 92 patients; ⁸ Validation cohort, n = 81 
excluding allogenic Hematopoietic Stem Cell Transplantation patients; ⁹ Validation cohort, n = 242 medical cancer patients; ¹⁰ Validation 
cohort, n = 1257 including scheduled surgery patients; ¹¹ Validation cohort, n = 542 medical and emergency surgical patients only; ¹² 
Validation cohort, n = 717 patients; ¹³ Validation cohort, n = 336 without scheduled surgical patients; ¹⁴ Validation cohort n = 981; ¹⁵ 
Validation cohort, n = 70, non-scheduled surgery patients; ¹⁶ Validation cohort, n = 911, scheduled surgery patients; *NP – Not provided; ** 
Og = other goodness-of-fit test performed; *** NI = not indicated. 
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Appendix F. Characteristics of the Validated Studies Included in Meta-Regression 
Study Country Location(s) Study 
Period 
Setting(s) Sample 
Size 
 (# of 
patients) 
 
Cancer Type Study Type Type of 
prediction 
modeling  
Statistical 
Software 
 
Benoit,  
et al (2003) 
Belgium 1 university 
hospital 
Jan 1997 to 
June  2000 
Adult 
MICU* 
146 Solid & 
hematologic 
malignancy 
Retrospective 
cohort study 
EVꭞ SPSS 9.0 
Berghmans,  
et al (2004) 
Belgium 1 oncology 
specialty 
hospital 
Jan 1999 to 
June 2000 
Adult**  
MICU-O 
247 Solid & 
hematologic 
malignancy 
Prospective cohort 
study 
EV Not 
indicated 
Can,  
et al (2008) 
Turkey 1 tertiary 
community 
hospital 
Sept 
2003 to 
March 
2006 
Not 
indicated 
224 Colorectal 
cancer (surgical 
resection) 
Prospective cohort 
study 
EV SPSS 11.0 
Cardenas-
Turanzas, 
et al (2012) 
USA 1 university-
affiliated, 
oncology 
specialty 
hospital 
Jan 2006 to 
Dec  2008 
Adult***  
MSICU 
6645 Hematologic 
and solid 
malignancy 
Cross-Validation, 
Retrospective 
cohort study 
PMꭞ ꭞ 
(n = 2069, medical) + 
(n = 3253, surgical) 
with EV 
(n = 540) + 
(n = 783, surgical) 
PASW 17.0 
Cornet,  
et al (2005) 
Netherlands 1 university 
hospital 
Nov 1995 
to Dec 
2002 
Adult 
MICU 
58 Acute Myeloid 
Leukemia and 
non-Hodgkin 
lymphoma 
Retrospective 
cohort study with 
prospective 
follow-up 
EV Not 
indicated 
Ertan,  
et al (2008) 
Turkey 1 university 
hospital 
Jan 1998 to 
July 2004 
Not 
indicated 
102 Colorectal 
cancer 
Retrospective 
cohort study 
EV Not 
indicated 
Fang,  
et al (2014) 
China 1 tertiary 
community 
hospital 
1991 – 
2011 
 
Adult*ꭞ  
ICU-NS 
851 Gastric cancer 
(surgical 
resection) 
Retrospective 
cohort study 
EV STATA 
11.0 
Greenberg,  
et al  (2016) 
USA 1 university-
affiliated 
hospital 
 
Sept 2009 
to Sept 
2014 
Adult 
MICU 
246 Hematologic 
malignancy 
Retrospective 
cohort study 
PM 
 (n = 50) with EV 
(n = 196) 
STATA 
13.1 
Hampshire, 
et al (2009) 
United 
Kingdom 
178 
hospitals 
Dec 1995 
to March 
Adult  
MSICU 
7,689 Solid & 
hematologic 
Retrospective 
cohort study 
EV STATA 9.2 
129 
 
2007 malignancy 
Kopterides, 
et al (2011) 
Greece  1 university 
hospital & 1 
tertiary 
hospital 
Jan 2005 to 
Dec 2007 
Adult  
MSICU 
126 Solid & 
hematologic 
malignancy  
Prospective 
observational 
study 
EV SPSS 10.0 
& MedCalc  
16.6 
Lamia, 
et al (2006) 
France 1 university 
hospital 
Jan 2000 to 
July 
2003 
Adult 
MICU 
92 Hematologic 
malignancy 
Retrospective 
cohort study 
EV STATA 8.0 
Liborio, 
et al (2011) 
Brazil 1 oncology 
specialty 
hospital 
May 2006 
to June 
2008 
Adult**ꭞ   
MSICU-O 
288 Solid & 
hematologic 
malignancy 
Prospective 
observational 
study 
EV SPSS 17.0 
Merz, 
et al (2008) 
Switzerland  1 university 
hospital 
July 2001 
to July 
2005 
Adult  
MSICU 
101 Hematologic 
malignancy 
Retrospective 
cohort study 
EV SPSS 13.0 
Namendys-
Silva, 
et al (2010) 
Mexico 1 oncology 
specialty 
hospital 
Jan 2007 to 
Oct 2007 
Adult  
MSICU-O 
117 Solid 
malignancy 
Prospective 
observational 
study 
EV SPSS 15.0 
Namendys-
Silva, 
et al (2012) 
Mexico 1 oncology 
specialty 
hospital  
Jan 2007 to 
Oct 2007 
Adult  
MSICU-O 
52 Gynecological 
cancer 
Prospective 
observational 
study 
EV SPSS 15.0 
Pohlen,  
et al (2016) 
Germany 3 university-
affiliated, 
hospitals 
Nov 2004 
to Sept 
2011 
Adult  
ICU-NS 
451 Acute Myeloid 
Leukemia 
Cross-Validation, 
Retrospective 
cohort study 
PM 
 (n = 187) with 
EV (n = 264) 
 
SPSS 22.0 
 
 
 
Schellongowski 
et al (2004) 
Austria 1 university 
oncology 
specialty 
hospital 
March 
1998 and 
July 2002 
Adult  
MSICU 
242 Solid & 
hematologic 
malignancy 
Prospective 
cohort study 
EV SAS 
Sculier,  
et at (2000) 
Belgium 1 oncology 
specialty 
hospital 
 
Oct 1992 to 
Aug  1995 
Adult  
MICU-O 
261 Solid & 
hematologic 
malignancy 
Prospective 
cohort study 
EV Not 
indicated 
Soares,  
et al (2004) 
Brazil 1 oncology 
specialty 
hospital 
May 2000 
to July 
2003 
 
Adult  
MSICU-O 
1972 Solid & 
hematologic 
malignancy 
Prospective 
observational 
study 
EV SPSS 10.0 
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Study Country Location(s) Study 
Period 
Setting(s) Sample 
Size 
 (# of 
patients) 
 
Cancer Type Study Type Type of prediction 
modeling  
Statistical 
Software 
 
Soares,  
et al (2010) 
Brazil 28 Hospitals Aug 2007 
to Sept 30, 
2007 
Adult  
MSICU 
(n = 23) & 
Adult  
MSICU-O 
(n = 5) 
717 Solid & 
hematologic 
malignancy 
Prospective 
multi-center 
cohort study 
 
 
 
 
EV Not 
indicated 
Xing,  
et al (2015) 
China 1 university-
affiliated, 
oncology 
specialty 
hospital 
Oct 2008 to 
Sept 
2010 
Adult  
MSICU 
981 Solid 
malignancy  
Retrospective 
cohort study 
EV SPSS 16.0 
Yan,  
et al (2012) 
China 2 university-
affiliated, 
hospitals 
Jan 2005 to 
Dec 2009 
Adult  
ICU-NS 
1695 Colorectal 
cancer (surgical 
resection) 
Retrospective 
Cohort study 
EV SPSS 19.0 
*Adult MICU = Adult Medical Intensive Care Unit; **Adult MICU-O = Adult Oncology Medical Intensive Care Unit; ***Adult MSICU = Adult Medical and Surgical Intensive 
Care Unit; *ꭞ Adult ICU-NS = Adult Intensive Care Unit – Not Specified; ** ꭞAdult MSICU-O = Adult Oncology Medical and Surgical Intensive Care Unit; ꭞ External validation = 
to assess and compare the predictive performance of an existing prediction model using new participant data; ꭞ ꭞ Prediction model = the development of the model is followed by 
quantifying the model’s predictive performance in participant data external to the development dataset. 
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